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Abstract
Upon oncogenic stress, the tumor suppressor Arf can induce irreversible cell cycle arrest
or apoptosis, depending on the oncogenic insult. In this study, it could be shown that
Arf interacts with Myc and the Myc-associated zinc finger protein Miz1 to facilitate
repression of genes involved in cell adhesion. Formation of a DNA-binding Arf/Myc/Miz1
complex disrupts interaction of Miz1 with its coactivator nucleophosmin and induces
local heterochromatinisation, causing cells to lose attachment and undergo anoikis. The
assembly of the complex relies on Myc, which might explain why high Myc levels trigger
apoptosis and not cell cycle arrest in the Arf response. This mechanism could play an
important role in eliminating cells harboring an oncogenic mutation.
Arf furthermore induces sumoylation of Miz1 at a specific lysine by repressing the desumoy-
lating enzyme Senp3. A sumoylation-deficient mutant of Miz1 however does not show phe-
notypic differences under the chosen experimental conditions. Myc can also be modified
by Sumo by multisumoylation at many different lysines, which is unaffected by Arf. The
exact mechanism and effect of this modification however stays unsolved.

Zusammenfassung
Der Tumorsuppressor Arf wird durch onkogenen Stress induziert und kann entweder einen
irreversiblen Zellzyklusarrest oder Apoptose auslösen. In dieser Arbeit konnte gezeigt
werden, dass Arf mit Myc und dem Myc-interagierenden Zinkfingerprotein Miz1 assoziiert
und dadurch Gene der Zelladhäsion reprimiert. Die Ausbildung eines DNA-bindenden
Arf/Myc/Miz1 Komplexes verhindert eine Interaktion von Miz1 mit seinem Koaktivator
Nucleophosmin und führt zur lokalen Ausbildung von Heterochromatin, was zum Ablösen
der Zellen und schließlich zur Anoikis führt. Die Komplexbildung setzt die Beteiligung
von Myc voraus, was erklären könnte warum hohe Mengen an Myc über Arf Apoptose
und nicht Zellzyklusarrest auslösen. Dieser Mechanismus könnte eine wichtige Rolle bei
der Eliminierung von Zellen mit einer onkogenen Mutation spielen.
Arf induziert darüber hinaus die Sumoylierung von Miz1 an einem bestimmten Lysin indem
es das desumoylierende Enzyme Senp3 inhibiert. Eine Mutante von Miz1 die nicht mehr
sumoyliert werden kann zeigt jedoch in den durchgeführten Untersuchungen keinen anderen
Phänotyp als Wildtyp Miz1. Myc kann ebenfalls an vielen verschiedenen Lysinen mit Sumo
modifiziert werden, wobei Arf jedoch keine Rolle spielt. Der genaue Mechanismus und
Effekt dieser Modifikation konnte jedoch nicht geklärt werden.

Chapter 1.
Introduction
Cancer is the leading cause of death in economically developed countries. About 12.7
million cases of cancer and 7.6 million cancer-related deaths have occured in 2008
[Ferlay et al., 2010]. In a medical sense cancer is a broad group of diseases all involving
unrestrained cell growth, and this is facilitated by accumulation of mutations. In order
to transform a normal cell into a cancer cell, the genes which regulate cell growth
and differentiation must be altered. According to their function, the genes involved in
these processes are categorized into proto-oncogenes and tumor suppressors. The latter
inhibit for example cell division and induce apoptosis. The most prominent member of
this group is p53, the guardian of the genome which is stabilized by another tumor
suppressor called Arf. Proto-oncogenes in contrast promote cell growth and cell division
and can become oncogenes if expressed at inappropriately high levels or upon aquiring
novel properties. The genes of the MYC family belong to some of the most potent and
frequently deregulated oncogenes [Croce, 2008].
Posttranslational modifications (PTMs) play a central role in the development of cancer.
Phosphorylation, ubiquitination and sumoylation for example have all been linked to cer-
tain aspects of tumorigenesis. PTMs are vital to processes such as alterations in gene
expression, modulation of cellular signaling pathways and regulation of cell division or
death which all are critical processes during neoplastic transformation. They are highly
suitable to be used as cancer biomarkers or therapeutic targets. There are numerous clini-
cal trials currently underway that are based on pharmacologically impeding tumor growth
by interrupting a specific PTM. It is thus of great importance in terms of application to
cancer detection and treatment to discover new posttranslational modifications on specific
targets [Krueger and Srivastava, 2006].
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1.1. Sumoylation
The Sumo protein was initially identified as a posttranslational modifier protein in the
mid-1990s, when Sumo was found to covalently attach to RanGAP1 [Matunis et al., 1996;
Mahajan et al., 1997]. Sumo stands for small ubiquitin-like modifier and is conjugated
to different target proteins to alter their function [Hay, 2005]. Due to its structural and
sequence similarities to ubiquitin, it is classified as a member of the ubiquitin-like proteins
[Kerscher et al., 2006]. Several hundred Sumo targets are known and the sumoylation
of a protein can have various different outcomes [Geiss-Friedlander and Melchior, 2007].
Sumoylation is essential for the viability of many different organisms, such as Caenorhabdi-
tis elegans [Jones et al., 2002], Drosophila melanogaster [Apionishev et al., 2001] and Mus
musculus [Nacerddine et al., 2005].
1.1.1. The Sumo family
Sumo proteins are around 10 kDa in size and their overall structure closely resembles that
of ubiquitin, even though they share only 18% sequence identity [Geiss-Friedlander and
Melchior, 2007; Bayer et al., 1998]. Lower eukaryotes have only one single sumo gene,
whereas plants and vertebrates express several sumo paralogues. Four Sumo proteins have
been described in mammals: Sumo1, Sumo2, Sumo3 and Sumo4. Sumo2 and Sumo3 are
98% similar in sequence and lack a clearly distinguishable functional difference; Sumo1
shares only about 50% sequence identity with Sumo2/3 [Wimmer et al., 2012]. Sumo4
shows a restricted pattern of expression in contrast to the other Sumo isoforms and its
functionality is still under debate [Wei et al., 2008; Owerbach et al., 2005]. With Sumo1 and
Sumo2/3 being as different as ubiquitin and NEDD8, it is not surprising that proteins are
selectively modified by the different Sumo isoforms and that these modifications can have
different consequences [Hay, 2007]. Nevertheless, they also share a substantial overlapping
set of target proteins [Vertegaal et al., 2006].
1.1.2. Mechanism of Sumo conjugation
A three-step enzymatic pathway attaches Sumo to specific targets, ultimately forming an
isopeptide bond between the C-terminal carboxyl group of Sumo and the -amino group of
a lysine side chain in the target protein [Johnson, 2004]. All Sumo proteins are translated
as immature precursors and need to be processed by specific isopeptidases to expose a
C-terminal diglycine motif. The heterodimeric E1 enzyme containing the SAE1 and SAE2
subunits adenylates the C-terminal glycine. Next, the Sumo adenylate is transferred to a
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cysteine in the E1 activating enzyme generating a thioester bond. Sumo is then passed on
to a cysteine in the E2 conjugating enzyme Ubc9. The E2 enzyme can directly transfer
Sumo to an acceptor lysine in the target protein forming an isopeptide bond, but E3
protein ligases often facilitate this process. They recruit a Sumo-loaded E2 enzyme and
the substrate into a complex and stimulate the E2 to discharge Sumo onto the target
[Gareau and Lima, 2010]. In contrast to ubiquitination, sumoylation only knows Ubc9 as
an E2 enzyme. Deletion of Ubc9 in mice results in early embryonic lethality with severe
abnormalities in nuclear structure and chromosome segregation, illustrating the importance
of an intact sumoylation pathway in mammals [Nacerddine et al., 2005].
Senp
Sumo
GGXXXX
Sumo
GG
SAE1
SAE2
Sumo
GG
Ubc9
Sumo
GG
Sumo
GG
Senp E3
Maturation
Activation
Transesterification
Ligation
Target
Deconjugation
Figure 1.1.:
The Sumo conjugation pathway
The Sumo precursor is processed by a Sumo specific protease (Senp) to expose the C-terminal diglycine
that is activated and conjugated to the E1 enzyme SAE1/SAE2. Sumo is transferred to the E2 enzyme
in a transesterification reaction, then discharged to a lysine in the target protein, often with the help of
an E3 enzyme. Sumoylation is a reversible process as Sumo can be deconjugated from the target protein
by the same proteases that also induce the maturation of Sumo. (adapted after Geiss-Friedlander and
Melchior [2007] and Hay [2005])
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1.1.3. Transferral of Sumo to a substrate
Many but not all proteins are sumoylated within a tetrapeptide Sumo consensus motif
[Hietakangas et al., 2006]. This motif is composed of Ψ-K-X-E/D, in which Ψ is a
hydrophobic residue, K is the lysine conjugated to Sumo, X is any amino acid which
is followed by an aspartic or glutamic acid (E/D). Most target lysines are modified
by a single copy of Sumo, however a consensus motif in Sumo2/3 which is absent in
Sumo1 allows the formation of poly-Sumo chains [Tatham et al., 2001]. The sumoylation
consensus motif directly interacts with Ubc9 and is sufficient for catalytic specificity of
Ubc9 in vitro. However, with some exceptions like the sumoylation of RanGAP1, Sumo
modification needs additional components next to the E1 and E2 enzymes to be efficient
[Bernier-Villamor et al., 2002; Lin et al., 2002].
Several proteins have been identified which can induce sumoylation by acting as Sumo E3
ligases. The biggest group of these are characterized by a SP-RING motif which resembles
the RING-domain of certain E3 ubiquitin ligases. The SP-RING directly attaches to Ubc9
and a Sumo-interacting-motif in the E3 ligase binds to Sumo, thereby creating a platform
for sumoylation [Hochstrasser, 2001]. Examples for SP-RING Sumo E3 ligases are the
PIAS family members, which have been shown to induce sumoylation of p53 [Kahyo et al.,
2001], Sp3 [Sapetschnig et al., 2002] and Mdm2 [Melchior and Hengst, 2000]. The nuclear
pore protein RanBP2 can induce sumoylation of RanGAP1, a GTPase activating protein
important for nuclear transport of proteins [Saitoh et al., 1997]. The Polycomb group
protein PC2 has been shown to sumoylate a transcriptional co-repressor called CtBP
and induce its localization into PcG bodies in the nucleus [Rytinki et al., 2009]. Other
proteins can induce sumoylation without interacting with Ubc9. The tumor suppressor
Arf can promote sumoylation of proteins to which it binds, for example nucleophosmin
[Haindl et al., 2008], Hdm2 [Xirodimas et al., 2002], the Werner helicase [Woods et al.,
2004] and the transcription factors E2F-1 and HIF-1α [Rizos et al., 2005]. It has been
shown that Arf induces sumoylation of nucleophosmin by decreasing the stability of a
Sumo deconjugating enzyme, Senp3, which in absence of Arf constantly removes Sumo
from NPM. Mechanistically, Arf promotes phosphorylation and subsequent ubiquitina-
tion of Senp3 which is then targeted for degradation by the proteasome [Haindl et al., 2008].
A large fraction of Sumo2/3 is constantly present as a free, non-conjugated pool, which
can be readily conjugated to proteins in response to stress stimuli such as heat shock,
oxidative stress and ethanol exposure. In contrast to that, the majority of Sumo1 exists
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in a conjugated rather than in a free form [Saitoh and Hinchey, 2000]. Even though there
are clear distinctions between Sumo1 and Sumo2/3 regarding their availability, target
specificity and their ability to form poly-Sumo chains, Sumo2/3 appear to be able to
substitute for Sumo1 in knockout mice. In contrast to Ubc9 knockout animals, Sumo1 null
mice are phenotypically normal [Zhang et al., 2008].
1.1.4. Removing Sumo from a substrate
Sumoylation is a highly dynamic process that can constantly be reversed by a group of
Sumo-specific proteases (Senps). It is the Senps that induce maturation of the Sumo
precursor proteins. They cut away a C-terminal amino acid extension to reveal the diglycine
motif needed for Sumo conjugation to a target. To balance the cellular abundance of a
particular sumoylated protein, Senps catalyze the removal of Sumo by cleaving the amide
bond between Sumo's C-terminus and the lysine in the sumoylated target. Humans have
six Senps which differ in localization and target specificity [Kim and Baek, 2009; Gareau
and Lima, 2010]. Senps are critical regulators of sumoylation and essential in mammals.
Proviral mutation of Senp1 in a mouse model increases steady-state levels of the sumoylated
form of several proteins and prevents proper embryonic development [Yamaguchi et al.,
2005].
1.1.5. Molecular consequences of sumoylation
Sumoylation can have different functional consequences for a target protein which are
impossible to predict. Modification by Sumo may influence the localization, activity
or stability of a modified protein. At the molecular level, sumoylation can have three
general consequences [Geiss-Friedlander and Melchior, 2007]. Sumoylation can interfere
with the binding to another protein meaning that interaction can occur only in absence
of modification with Sumo. For instance, the Sumo acceptor site of the transcriptional
repressor protein ZNF76 overlaps with its binding site for the TATA-binding protein
TBP [Zheng and Yang, 2004]. Sumoylation can also provide a new binding interface
for a partner protein. For instance, the acetyltransferase p300 can only interact with
HDAC6 when sumoylated [Girdwood et al., 2003]. Finally sumoylation can induce a
conformational change in the modified target, which so far has only been shown for the
thymine DNA glycosylase [Hardeland et al., 2002].
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1.1.6. Sumo and transcription factors
Although both Sumo1 and Sumo2/3 modulate many different cellular processes, a multi-
tude of their target proteins have been shown to be involved in transcriptional regulation
[Vertegaal et al., 2006]. Sumoylation can both activate and repress transcription. In most
cases, however, it leads to repression, with various models explaining how this is achieved
[Girdwood et al., 2004]. To illustrate these mechanisms, several examples of how Sumo
modification increases or represses transcriptional activation will be discussed here.
Examples of how sumoylation can activate transcription
The transcription factor Oct4 is a master regulator in the fate of stem cells and can also
have dramatic effects in oncogenesis, which is why it is tightly regulated. When Oct4
gets sumoylated by Sumo1 a fraction of this protein colocalizes with Sumo1 in nuclear
aggregates. Sumoylation increases the overall stability, DNA binding capacity and trans-
activation potential of Oct4 [Wei et al., 2007]. Another example for compartimentalization
and subsequent change in activity upon sumoylation has been shown for the heat shock
factors HSF1 and HSF2. These are normally retained inactive in a complex with heat
shock proteins. Upon heat stress they are released and can be sumoylated, which recruits
the HSFs into nuclear stress granules and increases their DNA binding and transactivation
capacity [Goodson et al., 2001; Hong et al., 2001].
Examples for transcriptional repression upon sumoylation
The Sp3 protein has been described either as an activator or repressor of transcription,
depending on the promoter context [Suske, 1999]. It was found that repression by
Sp3 occurs upon sumoylation mediated by the E3 ligase PIAS1. This goes along with
relocalization of Sp3 from a diffuse nuclear distribution to distinct nuclear dots and the
nuclear periphery [Sapetschnig et al., 2002]. Gene repression at sumoylated Sp3 binding
sites occurs because of local heterochromatinisation with a H3K9triMe and H4K20triMe
signature [Stielow et al., 2008].
Sumoylation also affects chromatin remodeling via the acetyltransferase p300, which
acts as a coactivator for several transcription factors such as Miz1 [Staller et al., 2001].
Sumoylation of p300 at two sites creates a new binding interface for the histone deacetylase
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HDAC6, which silences transcription. Interestingly, another HDAC, SIRT1, increases the
repressive effect by deacetylating the exact same lysines in p300 which are then free to be
sumoylated [Girdwood et al., 2003].
Another way of how sumoylation acts on transcription factors is by preventing other post-
translational modifications. This is the case for NF-κB, an important regulator of the
immune response. It is normally retained inactive by the inhibitory protein IκB in the
cytosol. Upon stimuli such as cytokine release, the Iκb kinase phosphorylates IκB which
is subsequently ubiquitinated and degraded and NF-κb is free to enter the nucleus and
activate transcription. Sumoylated Iκb is resistant to degradation, as Sumo blocks the
exact same lysine that is targeted for ubiquitination [Hay et al., 1999].
1.1.7. Non-covalent interactions with Sumo
In general, sumoylation alters the inter- and/or intramolecular interactions of a substrate
and hence its localization, activity or stability. Non-covalent interaction with Sumo is
needed to mediate these effects [Wimmer et al., 2012]. In contrast to ubiquitin, which
can be bound by a large number of different recognition domains, Sumo is exclusively
recognized by a short conserved motif called SIM (Sumo interacting motif), first described
by Minty et al. [2000]. SIMs can be classified into three major types: SIMa, SIMr and
SIMb. SIMa contains four consecutive hydrophobic amino acids, often in a V/I-X-V/I-V/I
motif, which is followed by a cluster of acidic residues. SIMr resembles SIMa but has a
reversed orientation, the four hydrophobic positions are preceded by an acidic stretch.
SIMb is better conserved and mostly follows the consensus sequence V-I-D-L-T and can
be for example found in PIAS E3 ligases [Miteva et al., 2010].
SIMs allow the recruitment of effector proteins to sumoylated targets, thus providing a
unique interaction platform [Wimmer et al., 2012]. The Sumo interacting motif is also
needed for E3 ligases like PIAS proteins to bring together Ubc9 and the sumoylation
target [Hochstrasser, 2001]. In the case of the ubiquitin protease USP25, a SIM is needed
to enable sumoylation of USP25 itself. Sumo-loaded Ubc9 is recruited to USP25 via an
internal SIM, which enables E3-independent conjugation of Sumo to lysine residues in
USP25. This mechanism is even more remarkable considering that the target lysines in
USP25 are non-consensus sumoylation sites [Mohideen and Lima, 2008].
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The Sumo interacting motif also allows for a crosstalk between the ubiquitination and
sumoylation pathways. In humans, the RING ubiquitin ligase RNF4 was identified as a
SUMO-targeted ubiquitin ligase (STUbL). RNF4 binds with four SIMs to polysumoylated
PML and subsequently mediates its ubiquitination and degradation via the proteasome.
This explains why patients with acute promyelocytic leukemia (APL) can be very effec-
tively treated with arsenic trioxide. These patients express a PML-RARα fusion protein
which blocks hematopoietic differentiation [Grignani et al., 1998]. Arsenic treatment
induces polysumoylation of PML, also in its fused form, which is subsequently recognized
and targeted to degradation by RNF4 [Tatham et al., 2008].
PML is also essential for the assembly and stability of PML bodies, which are nuclear
sumoylation hot spots. These nuclear bodies have been described as an intrinsic antiviral
defense mechanism, especially against DNA viruses. Immediate early proteins encoded
by the herpes simplex and cytomegalovirus genomes can induce dispersal of PML bodies,
these viral proteins contain Sumo interacting motifs. There are several more examples how
pathogens take advantage of the Sumo machinery, mostly by inhibiting its function and
therefore relieving a transcriptionally repressive environment that is induced by sumoyla-
tion [Wimmer et al., 2012].
1.1.8. The Sumo Enigma
A characteristic feature of sumoylation is that the biological consequences of Sumo
conjugation do not appear proportionate to the small fraction of substrate that is
modified, which often is only a few percent of a given protein [Hay, 2005; Johnson, 2004].
Even though sumoylation is a labile, short-lived modification it allows global, long-lasting
control of proteins [Wimmer et al., 2012]. One model explains this by assuming that upon
Sumo conjugation the target protein is immediately recruited into a repressive complex.
Shortly after the recruitment, Sumo could be deconjugated again while retaining the
target protein in the complex. This concept is supported by the rapid Sumo deconjugation
observed after expression of the adenoviral Gam-1 protein, which blocks the Sumo E1
enzyme [Boggio et al., 2004]. This means that there must be constant deconjugation of
Sumo modification going on in the cell. Another model suggests that a Sumo-modified
transcription factor could recruit chromatin-remodelling enzymes and thus create a
permanent repressive or activating environment without the need of constant sumoylation.
In both models, Sumo is required only for initiation but not for maintenance of the effect.
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Reactivation of a sumoylated protein targeted for repression could be triggered by
disassembly of the complex, probably induced by other posttranslational modifica-
tions such as acetylation or phosphorylation. This has been shown for example for
ELK-1. The MAP kinase-induced phosphorylation of ELK-1 results in loss of sumoy-
lation and escape of the transcription factor from the repressive complex [Yang et al., 2003].
In general, sumoylation often recruits factors required for assembly or disassembly of macro-
molecular complexes. Once incorporated into such a complex, the Sumo target protein may
rapidly lose its modification again. Thus, otherwise identical unmodified proteins may have
different properties depending on their history of modification by Sumo [Hay, 2005].
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1.2. The transcription factor Miz1
Miz1 is a zinc finger protein that was identified in a yeast two-hybrid screen as an inter-
actor of Myc and was therefore called MYC interacting zinc-finger-protein 1 [Schneider
et al., 1997]. In mice Miz1 is ubiquitously expressed and essential for survival, as Miz1 ho-
mozygous knockout animals are severely retarded in early embryonic development and not
viable [Adhikary et al., 2003]. In humans, high Miz1 levels are associated with favorable
disease outcome for example in neuroblastoma, which points to a role of Miz1 as a tumor
suppressor in this type of cancer [Ikegaki et al., 2007].
1.2.1. Miz1 protein structure
Miz1 is a member of the BTB/POZ (poxvirus and zinc-finger/ bric-à-brac, tramtrack, broad
complex ) zinc finger transcription factors. The N-terminal BTB/POZ domain acts as a
hydrophobic interaction surface for di- and tetramerization of Miz1 itself and binding to
other proteins for example of the POZ family [Stead et al., 2007]. In contrast to other POZ
proteins Miz1 is expressed in a soluble form residing predominantly in the nucleoplasm,
however it can also be found in the cytoplasm where it can interact with microtubuli
[Ziegelbauer et al., 2001]. The C-terminal DNA binding domain of Miz1 consists of 12
consecutive Cys2His2 zinc fingers, separated from an isolated 13th zinc finger by an alpha-
helical buffer region of 80 amino acids. The buffer region and a stretch of residues N-
terminal to the first 12 zinc fingers mediate the binding to important Miz1 interaction
partners such as c-Myc and p300 [Peukert et al., 1997; Staller et al., 2001].
1 ZF 1-12 ZF 13
Miz1
803
Myc, p300
binding region
306 637
TopBP1, NPM, HectH9, Bcl6 binding region
BTB/
POZ
Figure 1.2.:
Schematic diagram of the Miz1 protein
Human Miz1 consists of 803 amino acids and contains an amino-terminal BTB/POZ domain and 13 zinc fingers
(ZF). The binding sites for several protein interactors are indicated by the brackets.
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1.2.2. Transcriptional regulation by Miz1
ChIP-seq analysis revealed that Myc is bound to an estimated number of 30.000 sites in
the human genome, whereas Miz1 binds strongly to about 800 sites. There are about
500 joint Miz1/Myc binding sites, the remaining 300 Miz1 only sites are mostly far away
from promoters. This indicates an important role of Myc in the transcriptional activity
of Miz1 and probably vice versa, which appears to be dose-dependent but has not been
completely elucidated yet [Walz and Wolf, 2012]. Miz1 binds close to the transcriptional
start site of RNA polymerase II dependent target genes such as CDKN2B, CDKN1A or
p57Kip2, which encode the p15ink4b, p21Cip1 and p57Kip2 cell cycle inhibitors [Seoane
et al., 2001, 2002; Adhikary et al., 2003]. Miz1 binding to DNA is followed by recruitment
of coactivators such as nucleophosmin or the histone acetyltransferase p300 to activate
transcription [Wanzel et al., 2008; Staller et al., 2001].
Miz1 activity can be modified in various ways. TopBP1 for example can act as a
negative regulator of Miz1 by retaining it in an inactive complex. DNA damage signaling
disrupts this complex by recruiting TopBP1 to the damage sites, which frees Miz1 to
activate transcription of the cell cycle inhibitor p21 [Herold et al., 2002]. In B cells, Miz1
heterodimerizes with Bcl6 to repress transcription of the Miz1 target CDKN1A. This
counteracts a p53-induced cell cycle arrest, which is activated in response to class switch
recombination events in mature B cells [Phan et al., 2005].
Two more major mechanisms of Miz1 regulation will be explained here in more detail, the
L23-nucleophosmin regulatory circuit and the Myc-mediated repression.
Regulation of Miz1 transactivation by L23 and nucleophosmin
Nucleophosmin (NPM) is a critical regulator of ribosome biogenesis. It acts as a nucleolar
endoribonuclease by inducing maturation of 47S rRNA and it directs the nuclear export of
both ribosomal subunits [Savkur and Olson, 1998; Maggi et al., 2008]. It also functions as
a chaperone for the highly basic Arf protein in the nucleolus [Colombo et al., 2005]. In the
nucleoplasm, it is an essential coactivator of Miz1. NPM binds to the POZ domain of Miz1
which enables expression of the cell cycle inhibitors p15ink4b and p21Cip1. The ribosomal
protein L23 inhibits Miz1-dependent transactivation by retaining nucleophosmin in the
nucleolus. High levels of L23 therefore inhibit G1 arrest induced by Miz1. Interestingly,
the L23 protein is encoded by a direct target gene of Myc, providing a feedback mechanism
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that links Myc-induced translation of ribosomal proteins to Miz1-dependent cell cycle arrest
[Wanzel et al., 2008].
Repression of Miz1 transactivation by Myc
Miz1-dependent gene expression can be inhibited by direct binding of Myc. This is
mediated by interaction of the helix-loop-helix domain of Myc with two regions in Miz1
flanking the twelve core zinc fingers (see Fig. 1.2). Miz1 binds to and therefore recruits
the Myc/Max heterodimer to the promotors of p21Cip1 and p15ink4B, which induces
transcriptional repression [Herold et al., 2002; Peukert et al., 1997; Staller et al., 2001]. A
point mutant of Myc, Myc V394D disrupts the binding and therefore lacks the repressive
effect on Miz1 [Herold et al., 2002]. Mechanistically, the association of Myc to Miz1 blocks
binding of coactivators such as the histone acetyltransferase p300 and nucleophosmin to
Miz1 [Wanzel et al., 2008].
Miz1 repression by Myc is important for the resistance of Myc-transformed cells to the
antiproliferative effects of TGF-β. Smad proteins activated upon TGF-β signaling bind to
the promotor region of CDKN2B, where they interact with Miz1 and activate transcription
[Seoane et al., 2001]. Myc can repress this by inducing a repressive Sp1/Smad/Myc
complex and by blocking recruitment of coactivators to Miz1 as described above [Feng
et al., 2002]. However, elevated levels of TGF-β can decrease Myc expression by direct
binding of the cytokine to a TGF-β- responsive element within the Myc promotor [Chen
et al., 2002; Gomis et al., 2006]. T-cell lymphomas that express high levels of TGF-β are
addicted to Myc, because it is needed to constantly inhibit expression of cell cycle
inhibitors via Miz1 [van Riggelen et al., 2010].
Myc-mediated repression of Miz1 in keratinocytes
A connection between the TGF-β signaling pathway and Myc-mediated repression of Miz1
could be confirmed in keratinocytes. Using the Myc V394D (Myc VD) mutant deficient
in Miz1 binding, it could be shown that Miz1 is required as a mediator for the repressive
effects of Myc in response to TGF-β. Microarray analysis revealed that in keratinocytes
Myc wild type but not Myc VD inhibits genes involved in cell-cell and cell-matrix adhesion,
which induces premature terminal differentiation and finally loss of epidermal stem cells
in the skin [Gebhardt et al., 2006]. Thus, interaction between Myc and Miz1 must be
tightly controlled during skin differentiation. High Myc expression in basal epidermal
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layers induces loss of adhesion and exit of cells from the stem cell compartment induced
by Miz1 [Gebhardt et al., 2006; Frye et al., 2003].
1.2.3. Transcription-independent functions of Miz1
Miz1 was initially described as a transcription factor, but it also exerts transcription-
independent functions, two examples of which will be described here.
The ubiquitin ligase HectH9 (also called Arf-BP1 or Mule) was found to interact with
the POZ domain of Miz1 in a yeast two-hybrid screen. HectH9 catalyzes attachment of
K63-linked polyubiquitin chains to the Miz1 interacting protein c-Myc, which enhances
its transcriptional activity. Miz1 antagonizes binding and activation of c-Myc by HectH9
because it competes with Myc for binding to the ubiquitin ligase [Adhikary et al., 2005].
Miz1 also acts as a signal- and pathway-specific modulator or regulator (SMOR) in the
pleiotropic TNF-α/JNK1 pathway. Miz1 prevents TNF-α- induced JNK1 activation and
induction of apoptosis by inhibiting ubiquitination of TRAF2 with K63-linked chains. The
regulation by Miz1 is highly specific, as it does not affect JNK activation by other factors
than TNF-α and has no influence on other branches of TNF-α signalling. Interestingly,
Miz1 itself is rapidly degraded in the proteasome upon TNF-α stimulation, suggesting that
it is part of a network that regulates the kinetics of JNK-induced activation and cell death
[Liu et al., 2009].
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1.3. The oncogenic transcription factor Myc
C-Myc was identified as the cellular homologue of the transforming viral oncogene v-myc
which induces myelocytomatosis in chicken [Sheiness and Bishop, 1979; Vennstrom et al.,
1982]. The Myc oncoprotein family comprises also N- and L-Myc [Sugiyama et al., 1989].
Myc is evolutionary highly conserved, it is expressed in all vertebrates and can even be
found in Drosophila melanogaster [Gallant et al., 1996]. It is indispensable for embryonic
development: homozygous deletion of c-Myc is embryonic lethal between day 8.5 and 9.5
[Davis et al., 1993], N-Myc-deficient mice die around day 11.5 [Sawai et al., 1993].
Elevated levels of active c-Myc can be observed in about 70% of all human tumors with
different causative mechanisms. Increased Myc protein levels in more than 80% of human
colon carcinomas for example are based on mutation of the APC gene which induces
accumulation of β-catenin and thus results in increased MYC expression [He et al., 1998].
Amplification of the MYC gene leads to development of solid tumors such as mamma
carcinomas [Park et al., 2005], small cell lung carcinomas [Yamada et al., 2000] or nodular
malignant melanomas [Treszl et al., 2004]. In leukemias and lymphomas overexpression of
Myc is often caused by translocations [Vita and Henriksson, 2006]. For instance, in 80%
of Burkitt's Lymphoma the t(8;14)(q24;q32) chromosomal translocation places the MYC
coding region under the control of immunoglobulin gene enhancer elements [Dalla-Favera
et al., 1982].
1.3.1. Structural and functional domains of the Myc protein
Myc proteins contain a C-terminal basic helix-loop-helix/leucine zipper domain
(bHLH/LZ). This domain mediates sequence-specific DNA binding and heterodimerisation
with another bHLH/LZ protein, Max (Myc-associated factor-X) [Blackwood and Eisen-
man, 1991]. The same region also allows for interaction with cofactors such as p300, Miz1
and CBP [Peukert et al., 1997; Vervoorts et al., 2003]. The amino terminal domain of Myc
contains additional conserved elements, the so called Myc boxes I-IV. These mediate im-
portant functions such as Myc-induced apoptosis [Evan et al., 1992], transformation [Stone
et al., 1987] and inhibition of differentiation [Freytag et al., 1990]. More precisely, Myc box
I is essential for the transformation of primary rat fibroblasts by Myc and Ras [Stone et al.,
1987]. Furthermore it plays an important role in Myc stability as it contains the phos-
phorylation sites threonine 58 and serine 62, which mediate binding of the ubiquitin ligase
Fbw7 and thus enable proteasomal degradation of Myc [Sears et al., 2000; Welcker et al.,
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2004b; Yada et al., 2004]. Myc box II serves as a binding platform for several interaction
partners such as TRRAP (transactivation/transformation-associated protein) [McMahon
et al., 1998], TIP48/49 (TBP interacting protein) [Wood et al., 2000] and Skp2 (S-phase
kinase-associated protein 2) [Kim et al., 2003; von der Lehr et al., 2003] and is needed for
transformation as well as transcriptional activation and repression by Myc. Myc boxes III
and IV are crucial in modulating Myc-induced transformation and apoptosis [Herbst et al.,
2005; Cowling et al., 2006].
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Figure 1.3.:
Schematic diagram of the Myc protein
Human c-Myc consist of 439 amino acids and contains several conserved regions: Myc boxes I-IV (MB I, II, III,
IV), a basic region (BR), a helix-loop-helix motif (HLH) and a leucine zipper (LZ). The binding sites for several
protein interactors are indicated by the brackets.
1.3.2. Transcriptional regulation by Myc
C-Myc has been shown to be a weak but expansive transcription factor that activates
or represses transcription of about 10% of the human genome. Myc has a broad range of
target genes which however are typically regulated by less than twofold. It influences many
different cellular processes such as proliferation and differentiation, ribosome biogenesis
and protein synthesis, metabolism and genomic stability, cell adhesion, angiogenesis and
apoptosis [Cole and Cowling, 2008].
Activation by Myc
For transcription of RNA polymerase I- and II-dependent target genes, the Myc/Max het-
erodimer binds to promoter sequences called E-boxes, which can be canonical (CACGTG)
or non-canonical (such as CACGTT or CACATG) [Blackwell et al., 1990, 1993]. For
Drosophila melanogaster also a Max-independent activation of RNA polymerase III-
transcribed target genes has been described [Gallant and Steiger, 2009]. Transcriptional
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activation by Myc involves recruitment of different coactivators such as the histone acetyl-
transferases CBP, GCN5, Tip60 and the ATPases Tip48/Tip49 [Adhikary and Eilers, 2005;
Cole and Nikiforov, 2006], resulting in an open chromatin structure and therefore enabling
transcription of target genes [Lee and Workman, 2007]. Additionally, Myc induces tran-
scriptional activation by binding to the mediator complex and to the transcription elonga-
tion factor P-TEFb, thus enabling recruitment of RNA polymerase II to the promoter and
allowing entry into the elongation phase [Bouchard et al., 2004; Eberhardy and Farnham,
2001].
Repression by Myc
Transcriptional repression by Myc is less well understood but essential for Myc-induced
apoptosis and transformation [Patel and McMahon, 2006, 2007; Staller et al., 2001; Wu
et al., 1999]. Transformation occurs because Myc represses a variety of genes from cell
adhesion, cell-cell communication and inhibition of cell cycle progression [Frye et al., 2003;
Gebhardt et al., 2006; Knoepfler et al., 2002; Wilson et al., 2004]. In general, Myc appears
to repress genes by binding to their core promoter region. One mechanism of transcrip-
tional repression is based on association of Myc to a transcriptional activator which is
thus transformed to a repressor. This applies for example for Miz1 [Schneider et al., 1997]
and Sp1 [Gartel et al., 2001], where Myc acts by displacing activating cofactors and by
recruiting repressive cofactors [Lüscher and Vervoorts, 2012]. Earlier studies suggested this
to be independent of Myc binding to the DNA, more recent studies provide evidence that
repression requires Max and E-boxes [Mao et al., 2003; Herkert and Eilers, 2010]. Next to
Miz1 and Sp1, other interaction partners of Myc have been identified which are blocked in
their transactivation function by Myc, such as FoxO3a [Chandramohan et al., 2008], YY-1
[Shrivastava et al., 1993], TFII-Ip107/E2F [Luo et al., 2004] and NF-Y [Izumi et al., 2001].
1.3.3. Myc-induced apoptosis
Among its many functions Myc can also elicit apoptosis, which is thought to be a protective
mechanism against oncogenic transformation [Askew et al., 1991; Evan et al., 1992; Murphy
et al., 2008; Pelengaris et al., 2002]. Apoptosis induction by Myc involves transcriptional
activation of the pro-apoptotic proteins Bax [Mitchell et al., 2000] and Bim [Egle et al.,
2004] and repression of the anti-apoptotic proteins Bcl2 and Bcl-xL [Eischen et al., 2001a,b].
Elevated levels of c-Myc additionally increase expression of the tumor suppressor Arf and
thus lead to stabilization of p53 [Zindy et al., 1998], which can either induce a reversible
cell cycle arrest or apoptosis. High levels of Myc repress the cell cycle inhibitor p21 via
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Miz1, which also is a prime target of p53 to induce G1 arrest [El-Deiry et al., 1993].
The anti-apoptotic Bcl2 is also a Miz1 target gene which is repressed by formation of the
Miz1/Myc complex [Patel and McMahon, 2006, 2007]. Elevated Myc levels could thus
favor the outcome of p53 activation against cell cycle arrest and towards activation of
pro-apoptotic target genes. This notion is supported by observations based on human
tumor samples and mouse models showing that a cooperation of Bcl-2 and Myc takes
place during tumorigenesis [Eischen et al., 2001b; Knezevich et al., 2005; Letai et al., 2004;
Martín-Subero et al., 2005].
1.3.4. Regulation of Myc function
It is well established that deregulated Myc plays a significant role in human cancer de-
velopment and maintenance. Normal cells only express the MYC gene when dividing
actively or upon stimulation by growth factors and reentry of the cell cycle [Kelly et al.,
1983; Marcu et al., 1992]. In cancer cells, Myc can be deregulated by any one of several
mechanisms that target the expression or activity of Myc directly or indirectly [Meyer and
Penn, 2008]. Several means of regulation on a transcriptional, post-transcriptional and
post-translational level that normally keep Myc under tight control will be discussed here.
Transcriptional regulation of Myc
Myc was identified as the first eukaryotic cellular gene to be regulated by a transcription
elongation block which occurs during cellular differentiation and can be defective in cancer
cells. The elongation block is executed as a reduction in the number of RNA polymerase II
complexes that read through sites of termination or pausing within exon 1 of the MYC
gene [Bentley and Groudine, 1986, 1988; Eick and Bornkamm, 1986].
TheMYC promoter is bound by many different transcription factors (summarized in Wier-
stra and Alves [2008]). One example is the transcriptional regulation by E2F factors upon
stimulation by viral oncoproteins E1A or large T [Hiebert et al., 1989; Thalmeier et al.,
1989]. As E2F is also a direct Myc target both factors can thus stimulate each other in a
positive feedback loop to allow entry into S phase. This induction by E2F can be repressed
again by the TGF-β signalling pathway [Fernandez-Pol et al., 1987].
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Post-transcriptional regulation of Myc
MYC mRNA is extremely unstable with a cytoplasmatic half-life of only about 20 minutes
[Dani et al., 1984]. An early step in degradation of MYC mRNA is poly(A) shortening
with subsequent mRNA destabilization and enzymatic decay [Brewer and Ross, 1988; Jones
and Cole, 1987]. A mechanism that stabilizes the mRNA is based on binding of CRD-BP
(coding region determinant-binding protein) at the carboxy-terminal region which protects
the ribonucleic acid from endonuclease attack [Bernstein et al., 1992]. Amplification of
CRD-BP was found in a variety of human tumors where it may be responsible for increased
Myc levels [Doyle et al., 2000; Ioannidis et al., 2001; Noubissi et al., 2006].
Translational regulation of Myc
There are multiple regulatory mechanisms that regulate translation of the MYC mRNA.
Its 5'UTR contains an IRES sequence (internal ribosome entry site) which promotes trans-
lation [Carter et al., 1999]. Several microRNAs interact with the 3'UTR of the MYC
mRNA, which either blocks translation or mediates degradation of the mRNA [Cannell
et al., 2010; Kress et al., 2011; Sachdeva et al., 2009; Sampson et al., 2007]. It was shown
that the microRNAs mir-34b and c which bind to the 3'UTR of Myc are activated in a
negative feedback loop by Myc itself. Myc transcriptionally induces the MK5 kinase that
phosphorylates and activates FoxO3a which subsequently induces miR-34b and c, thus in-
ducing proliferation arrest by lowering Myc levels. This mechanism can be deregulated in
colorectal carcinomas [Kress et al., 2011].
Regulation of Myc via protein stability
Similarly to the MYC mRNA, the Myc protein is highly unstable with a half-life of only
20 to 30 minutes [Hann and Eisenman, 1984]. The rapid protein degradation is regulated
by phosphorylation and ubiquitination of Myc [Hann, 2006; Vervoorts et al., 2006].
Initially, Myc is phosphorylated by MAP kinases at serine 62, which serves as a priming
site for Gsk3 (Glykogen Synthase Kinase 3). Gsk3 phosphorylates Myc at threonine 58
(T58), upon which it is recognized by the Fbw7 ubiquitin ligase and then ubiquitinated
and degraded in the proteasome [Lutterbach and Hann, 1994; Sears et al., 2000; Welcker
et al., 2004b,a]. This pathway is disrupted in Burkitt lymphomas harboring T58 or S62
mutations in the Myc sequence, leading to reduced ubiquitination and enhanced stability
of the Myc protein [Bahram et al., 2000].
1.3. The oncogenic transcription factor Myc 19
The SCF-β-TrCP complex catalyzes attachment of heterotypic ubiquitin chains to the N-
terminus of Myc, which antagonizes the SCF-Fbw7 mediated degradation and thereby leads
to stabilization of the oncoprotein [Popov et al., 2010]. Finally, the ubiquitin ligase HectH9
catalyzes linkage of K63-linked polyubiquitin chains to Myc which does not elicit protea-
somal degradation but recruitment of cofactors and transcriptional activation [Adhikary
et al., 2005].
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1.4. Objectives of the thesis
(1) Oncogenic activation of the Myc protein is one of the most frequent events on the way
to tumor development. To prevent malignant transformation, cells have evolved different
protective means of how to react to oncogenic stimuli. Arf triggers a p53-dependent path-
way that safeguards cells against hyperproliferative signals, but activation of this pathway
does not always have the same outcome. Constitutively active Ras for example activates
the INK4A/Arf locus and thus induces an irreversible cell cycle arrest named oncogene-
induced senescence [Palmero et al., 1998; Serrano et al., 1997]. Elevated Myc levels on the
other hand do not induce senescence but rather elicit apoptosis [Evan et al., 1992]. Myc
has been shown not only to activate but also to directly interact with the tumor suppressor
Arf [Zindy et al., 1998; Qi et al., 2004]. Transcriptional repression by Myc for example
via Miz1 also plays a role in Myc-induced apoptosis. Miz1 in turn has nucleophosmin as a
coactivator [Wanzel et al., 2008], and nucleophosmin is also major binding partner for Arf.
The first aim of this thesis was to explore a possible connection between the three proteins
Arf, Myc and Miz1. This may improve our understanding of why Myc primarily elicits
apoptosis as an oncogenic stress response.
(2) Posttranslational modifications have been linked to nearly all aspects of tumor devel-
opment and are highly suitable for use as cancer biomarkers or as therapeutic targets.
It is therefore vital to discover new modifications, especially on proteins closely linked
to tumorigenesis such as Miz1 and Myc. Both proteins exhibit characteristics making
them prone to be modified by sumoylation: nuclear Miz1 perfectly colocalizes with Sumo
upon Arf expression, Myc contains a highly conserved region that might act as a Sumo
interacting motif.
Therefore, the second aim of this thesis was to investigate wether Miz1 and Myc can be
regulated by sumoylation.
Chapter 2.
Materials
2.1. Strains and cell lines
2.1.1. Human cell lines
HeLa
Human cervix carcinoma cell line (ATCC)
U2OS
Human osteasarcoma cell line (ATCC)
Phoenix
Human packaging cell line for MoMuLV-retroviruses (Phoenix-Eco) [Kinsella and Nolan,
1996]
HEK293T
Human embryonic kidney cell line (ATCC)
LS174T
colorectal adenocarcinoma cell line (ATCC)
2.1.2. Bacterial strains
DH5α
Escherichia coli F-, φ80dlacZ∆M15, ∆(lacZYAargF)U169, deoR, recA1, endA1, hsdR17
(rk-,mk+), phoA, supE44, λ-, thi-1, gyrA96, relA1; for amplification of plasmids
XL1 blue
Escherichia coli, recA1, endA1, gyrA96, thi-1, hsdR17 supE44, relA1, lac [F'proAB
lacIqZ∆M15Tn10(Tetr)]; for generation and amplification of plasmids
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BL21
Escherichia coli, F- ompT gal dcm lon hsdSB(rB- mB-) λDE3 lacI lacUV5-T7 gene 1 ind1
sam7 nin5; for expression of GST fusion proteins
2.2. Cultivation media and supplements
2.2.1. Media for mammalian cell culture
Basal medium DMEM containing L-glutamine (584mg/ml) was purchased by Sigma.
Fetal bovine serum (FBS; from PAA) was heat inactivated for 30min at 56 °C before use.
Basal medium
DMEM 10% (v/v) FBS 1% (v/v) penicillin/ streptomycin (100,000U/ml; from PAA)
Freezing medium
90% (v/v) FBS 10% (v/v) DMSO
2.2.2. Antibiotics for mammalian cell culture
For selection of successfully transfected or infected cells they were treated with the
antibiotics given below. A resistance to neomycine was selected with G418, a bleomycine
resistance with zeocine.
Blasticidin S (InvivoGen) 5-10 μg/ml
G418 (PAA) 800 μg/ml
Puromycin (InvivoGen) 2 μg/ml
Hygromycin (Merck) 100 μg/ml
Zeocin (InvivoGen) 50-500 μg/ml
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2.2.3. Media and antibiotics for bacterial cell culture
Media
LB-medium
10% (w/v) bacto tryptone
0.5% (w/v) yeast extract
1% (w/v) NaCl
LB-agar
LB-medium
1.2% (w/v) Bacto-Agar
autoclaved, cooled down to 50 °C before adding ampicillin, 20ml poured into 10 cm dishes
Antibiotics
Depending on the resistance marker on the corresponding DNA plasmid, the following
antibiotics were added to the LB-medium or LB-agar:
Ampicillin 100 μg/ml
Kanamycin 100 μg/ml
Chloramphenicol 25 μg/ml
2.3. Nucleic acids
2.3.1. Primer
DNA-primers were synthesized either by Metabion or Sigma (f, fw, for = forward; r, rv,
rev = reverse). Primers for quantitative qRT-PCR were designed with the help of the
Universal Probe Library by Roche and are all intron-spanning to avoid amplification of
genomic DNA.
Table 2.1.: List of primers
name application sequence 5' to 3'
Mlu-Bam-Arf cloning cgacgcgtggatccatggtgcgcagg
Arf-EcoRI-RV cloning cggatatcgaattctcagccaggtccacggg
Miz1-K251R-fwd mutagenesis gggcgcagggccagctgaggtcagggaggagggttcccagctgg
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Table 2.1  continued from previous page
Miz1-K251R-rev mutagenesis ccagctgggaaccctcctccctgacctcagctggccctgcgccc
Miz1-K138R-Fwd mutagenesis ggaggggacaagagagccagagaggagaaggtggccaccagcacgc
Miz-K138R-Rev mutagenesis gcgtgctggtggccaccttctcctctctggctctcttgtcccctcc
Miz-K166R-Fwd mutagenesis ggccccagcagggacctcagggaggagcgcggcggtcaggccc
Miz-K166R-Rev mutagenesis ggccccagcagggacctcagggaggagcgcggcggtcaggccc
Miz1-K229-Fwd mutagenesis ggaggtggagcccgcccggagaggggaagaggagcaaaaggagc
Miz-K229R-Rev mutagenesis gctccttttgctcctcttcccctctccgggcgggctccacctcc
Miz1-K307R-Fwd mutagenesis ccaaggcctacggctccgtcatccacaggtgcgaggactgtgggaagg
Miz-K307R-Rev mutagenesis ccttcccacagtcctcgcacctgtggatgacggagccgtaggccttgg
Miz-K696R-Fwd mutagenesis gccgatgagacggaagtcctgagggccgagatcagcaaagctgtgaagc
Miz-K696R-Rev mutagenesis gcttcacagctttgctgatctcggccctcaggacttccgtctcatcggc
Miz1-K704R-Fwd mutagenesis cagcaaagctgtgaggcaagtgcaggaag
Miz1-K704R-Rev mutagenesis cttcctgcacttgcctcacagctttgctg
MizV250A-F-S mutagenesis gggcgcagggccagctgaggccaaggaggagggttcccagctgg
MizV250A-R-S mutagenesis ccagctgggaaccctcctccttggcctcagctggccctgcgccc
MizE253A-F-S mutagenesis gggcgcagggccagctgaggtcaaggaggcgggttcccagctgg
MizE253A-R-S mutagenesis ccagctgggaacccgcctccttgacctcagctggccctgcgccc
Myc-K326R-f mutagenesis ctatcctgctgccaagagggtcaggttggacagtgtcagagtcc
Myc-K326R-r mutagenesis ggactctgacactgtccaacctgaccctcttggcagcaggatag
Myc-K355R-f mutagenesis cggacaccgaggagaatgtcaggaggcgaacacacaacgtcttgg
Myc-K355R-r mutagenesis ccaagacgttgtgtgttcgcctcctgacattctcctcggtgtccg
Myc-K323R-f mutagenesis cggaaggactatcctgctgccaagagggtcaagttggacagtgtcag
Myc-K323R-r mutagenesis ctgacactgtccaacttgaccctcttggcagcaggatagtccttccg
Sumo1-D15V-f mutagenesis ccttcaactgaggacttgggggttaagaaggaaggtg
Sumo1-D15V-r mutagenesis caccttccttcttaacccccaagtcctcagttgaagg
Sumo2-K11R-f mutagenesis cgaaaagcccaaggaaggagtcaggactgagaacaacgatcatattaatttg
Sumo2-K11R-r mutagenesis caaattaatatgatcgttgttctcagtcctgactccttccttgggcttttcg
Sumo2-K33,35R-f mutagenesis ggatggttctgtggtgcagtttaggattaggaggcatacaccacttag
Sumo2-K33,35R-r mutagenesis ctaagtggtgtatgcctcctaatcctaaactgcaccacagaaccatcc
Sumo2-K42,45R-f mutagenesis ggcatacaccacttagtagactaatgagagcctattgtgaacgacagttgg
Sumo2-K42,45R-r mutagenesis ccaactgtcgttcacaataggctctcattagtctactaagtggtgtatgcc
Myc-K326R-f mutagenesis ctatcctgctgccaagagggtcaggttggacagtgtcagagtcc
Myc-K326R-r mutagenesis ggactctgacactgtccaacctgaccctcttggcagcaggatag
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Table 2.1  continued from previous page
Myc-K355R-f mutagenesis cggacaccgaggagaatgtcaggaggcgaacacacaacgtcttgg
Myc-K355R-r mutagenesis ccaagacgttgtgtgttcgcctcctgacattctcctcggtgtccg
MycK323,326Rf mutagenesis ggactatcctgctgccaggagggtcaggttggacagtgtcagagtcc
MycK323,326Rr mutagenesis ggactctgacactgtccaacctgaccctcctggcagcaggatagtcc
MycR323,326Kf mutagenesis ggactatcctgctgccaagagggtcaagttggacagtgtcagag
MycR323,326Kr mutagenesis ctctgacactgtccaacttgaccctcttggcagcaggatagtcc
MycR355K-fw mutagenesis cggacaccgaggagaatgtcaagaggcgaacacacaacgtcttgg
MycR355K-rv mutagenesis ccaagacgttgtgtgttcgcctcttgacattctcctcggtgtccg
MycR341K-fw mutagenesis gacagatcagcaacaaccgaaaatgcaccagccccaggtcc
MycR341K-rv mutagenesis ggacctggggctggtgcattttcggttgttgctgatctgtc
MycK341R-f mutagenesis gacagatcagcaacaaccgaagatgcaccagccccaggtcc
MycK341R-r mutagenesis ggacctggggctggtgcatcttcggttgttgctgatctgtc
cMyc-ADAA-fw mutagenesis caagaagatgaggaagaagccgatgctgcttctgtggaaaagaggcagg
cMyc-ADAA-rv mutagenesis cctgcctcttttccacagaagcagcatcggcttcttcctcatcttcttg
MycR317K-f mutagenesis cgcagcgcctccctccactcggaaggactatcctgctgcc
MycR317K-r mutagenesis ggcagcaggatagtccttccgagtggagggaggcgctgcg
MycR289K-f mutagenesis cttctgctggaggccacagcaaacctcctcacagcccactg
MycR289K-r mutagenesis cagtgggctgtgaggaggtttgctgtggcctccagcagaag
MycR430K-fw mutagenesis gacgagaacagttgagacacaaacttgaacagctacggaact
MycR430K-rv mutagenesis agttccgtagctgttcaagtttgtgtctcaactgttctcgtc
2.3.2. RNA oligonucleotides
Pools of four RNA oligonucleotides against UBC9 were purchased from Dharmacon
(ON-TARGETplus SMARTpool). As a control the siCONTROL (ON-TARGETplus
Non-targeting Pool) was used. Target sequences against UBC9 :
GGGAAGGAGGCUUGUUUAA
GAAGUUUGCGCCCUCAUAA
GGCCAGCCAUCACAAUCAA
GAACCACCAUUAUUUCACC
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2.4. Plasmids
2.4.1. Empty vectors
Table 2.2.: List of empty vectors
pcDNA 3.0 / pcDNA 3.1 Eucaryotic expression vector with CMV (cytomegalovirus)-
promoter (Invitrogen)
pBabe hygro/puro/bleo/neo Eucaryotic retroviral expression vector with LTR-promoter
and hygromycin-, puromycin-, bleomycin-, neomycin- resis-
tance (xxx Morgenstern and Land, 1990)
pGEX-4T3 Bacterial expression vector with tac-promoter for expression
of GST-tagged recombinant proteins (GE Healthcare)
peGFP N1 Eucaryotic expression vector with CMV (cytomegalovirus)-
promoter for generation of C-terminal eGFP-tagged fusion
proteins (Clontech)
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2.4.2. Expression vectors
Table 2.3.: List of expression vectors
pcDNA3 MIZ1 pcDNA3 with CDS of human MIZ1
pcDNA3 MYC pcDNA3 with CDS of human C-MYC
pcDNA3 HA-NPM pcDNA3 with CDS of human HA-tagged NPM
pcDNA3 His-SUMO2 pcDNA3 with CDS of human His-tagged SUMO2
pcDNA3 p14ARF pcDNA3 with CDS of human p14ARF
pcDNA3 SENP3 pcDNA3 with CDS of human SENP3
pcDNA3 TOPBP1 pcDNA3 with CDS of human TOPBP1
peGFP p14ARF 1-132 peGFP with CDS of human p14ARF
peGFP p14ARF 65-132 peGFP for expression of an N-terminal deletion mutant of
human p14ARF (aa 65-132)
pGL2 p15(-113/+160) pGL2 with the human p15Ink4b- promoter sequence from
-113 until +160 followed by the firefly luciferase gene
pGEX GST-MIZ1 pGEX-4T2 expression vector (GE Healthcare) with CDS of
human MIZ1
pGEX GST-SUMO1 pGEX expression vector (GE Healthcare) with CDS of hu-
man SUMO1
pGEX GST-SUMO2 pGEX expression vector (GE Healthcare) with CDS of hu-
man SUMO2
pRRL puro MIZ1 pRRL with puromycin resistance and CDS of human MIZ1
for lentiviral infection
pLV-red P14ARF pLV-red with CDS of human P14ARF for lentiviral infection
2.4.3. Lentiviral packaging vectors
Table 2.4.: List of lentiviral packaging vectors
psPAX2 plasmid coding for the lentiviral virion packaging system
(HIV gag, pol, rev)
pMD2.g plasmid coding for the lentiviral envelope (VSV-G env)
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2.5. Antibodies
WB: Western blot; IF: immunofluorescence; IP: immunoprecipitation;
mono: monoclonal; poly: polyclonal
m: mouse; r: rabbit
2.5.1. Primary Antibodies
Table 2.5.: List of primary antibodies
protein type application name
β-actin m, mono IgG1 WB AC15 (Sigma)
Cdk2 m, mono IgG1 WB M-2 (Santa Cruz)
GFP m, mono IgG1 WB G6539 (Sigma)
HA m, mono IgG1 WB 16B12 (Covance)
Miz1 m, mono WB, IF, IP 10E2 (group Eilers production)
c-Myc m, mono IgG WB, IF 9E10 (group Eilers production)
p14Arf r, poly WB, IF NB200-111 (Novus Biologicals)
Ubc9 r, poly WB Ab33044 (Abcam)
NPM1 m, mono WB, IF ab10530 (Abcam)
FLAG (M2) m, mono IgG1 WB, IF F3165 (Sigma)
N-Myc m, mono IgG2a WB B8.4.B (BD)
Sumo1 m, mono IgG1 WB 33-2400 (Invitrogen)
Sumo2 r, poly WB 57-9100 (Invitrogen)
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2.5.2. Secondary Antibodies
Table 2.6.: List of secondary antibodies
name application description
α-rabbit-HRP WB donkey-anti-rabbit-immunoglobulin coupled with
horseradish peroxidase (Amersham, NA 934)
α-mouse-HRP WB donkey-anti-mouse-immunglobulin coupled with
horseradish peroxidase (Amersham, NA 931)
α-mouse-Alexa488 IF goat-anti-mouse-immunglobulin conjugated with Alexa
Fluor 488 (Invitrogen, A11001)
α-mouse-Alexa647 IF goat-anti-mouse-immunglobulin conjugated with Alexa
Fluor 647
α-rabbit-Alexa488 IF goat-anti-rabbit-immunglobulin conjugated with Alexa
Fluor 488
α-rabbit-Alexa647 IF goat-anti-rabbit-immunglobulin conjugated with Alexa
Fluor 647
2.6. Chemicals
All chemicals were purchased from the companies Sigma, Merck, Roth, Acors Organics,
Invitrogen and Applichem and used without further purification.
2.7. Enzymes, standards and kits
2.7.1. Enzymes
DNase-free RNase A Quiagen
M-MLV reverse transcriptase Promega
Restriction endonucleases Fermentas, New England Biolabs
RNase-free DNase Fermentas
T4-DNA-Ligase Fermentas
Pfu Polymerase Fermentas
Pfu-Turbo Polymerase Stratagene
Phusion High Fidelity Polymerase Fermentas
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2.7.2. Standards
Protein marker PageRuler Prestained Protein Ladder (Fermentas)
DNA marker 1 kb DNA Ladder (Invitrogen)
2.7.3. Kits
JETSTAR 2.0 Plasmid Purification Maxi Kit Genomed
GeneJET Gel Extraction Kit Fermentas
RNeasy Mini Kit Quiagen
SYBR Green qPCR Master Mix Thermo Scientific
TnT Quick Coupled Transcription/Translation Systems Promega
Qiaquick PCR Purification Kit Qiagen
2.8. Buffers and solutions
Bacterial lysis buffer
50mM NaCl
50mM Tris base
5mM EDTA
Bacterial wash buffer
50mM Tris base
5mM EDTA
adjust to pH 8 with 6M HCl
1:1000 proteinase inhibitors (freshly added)
Blocking solution for PVDF membrane
5% (w/v) skim milk powder in TBS-T
Coomassie staining solution
25% (v/v) isopropanol
10% (v/v) acetic acid
0.05% (w/v) Coomassie G250 stain
Coomassie destain solution
10% (v/v) acetic acid
20% (v/v) methanol
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Crystal violet solution
0.1% (w/v) crystal violet
20% (v/v) ethanol
DNA loading buffer
40% (w/v) saccharose (pH 8.0)
0.2% (w/v) bromphenol blue
0.2% (w/v) xylene cyanol
10mM EDTA
GST binding buffer
25mM HEPES pH 7.6
100mM KCl
12.5mM MgCl2
20% Glycerin
0.05% NP40
1mg/ml BSA
1mM DTT
GST wash buffer
25mM HEPES pH 7.6
100mM KCl
12.5mM MgCl2
20% Glycerin
0.1% NP40
1.5mg/ml BSA
HBS (2x) for transfection
280mM NaCl
1.5mM Na2HPO4
50mM HEPES
adjusted to pH 7.4
sterile filtered
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Low salt lysis buffer
25mM glycylglycine
15mM MgSO4
4mM EGTA
1% (vol/vol) Triton X-100
Luciferase substrate solution
25mM glycylglycine solution
15mM K3PO4 (pH 8.0)
4mM EGTA
15mM MgSO4
75 μM D-luciferine
2mM ATP
1mM DTT
Mowiol solution
13.3% (w/v) Mowiol 4-88
33.3 % (v/v) glycerine
0.13M Tris (pH 8.5)
NP-40 lysis buffer
50mM Tris-HCl
150mM NaCl
1% NP-40
adjusted to pH 8.0
PBS
137mM NaCl
2.7mM KCl
10.1mM Na2HPO4
1.76mM KH2PO4
autoclaved
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PI-FACS-buffer
38mM sodium citrate
54 μM propidiumiodide
24 μg/ml Rnase A
Plasmid prep buffer 1
50mM Tris-HCl (pH 8.0)
100mM EDTA
100 μg/ml RnaseA
Plasmid prep buffer 2
200mM NaOH
1% (w/v) SDS
Plasmid prep buffer 3
3.1M potassium acetate (pH 5.5)
RIPA lysis buffer
150mM NaCl
1% (v/v) NP-40
0.5% (w/v) DOC
0.1% (w/v) SDS
50mM Tris (pH 7.5)
SDS sample buffer (3x)
187.5mM Tris (pH 6.8)
30% (v/v) glycerine
6% SDS (sodium dodecyl sulfate)
0.03% (w/v)bromphenol blue
2M β-mercaptoethanol
SDS running buffer
25mM Tris Base
250mM glycine
0.1% SDS
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Stripping buffer
62.5mM Tris (pH 6.8)
2% (w/v) SDS
100mM β-mercaptoethanol
Tank blot buffer (10x)
1.9M glycine
250mM Tris Base
0.05% SDS
adjusted to pH 8.0
TBS (20x)
500mM Tris Base
2.8M NaCl
adjusted to pH 7.4
TBS-T
0.2% Tween-20
25mM Tris, 140mM NaCl
adjusted to pH 7.4
TE
10mM Tris
1mM EDTA
adjusted to pH 8.0
TAE
40mM Tris
0.114% (v/v) acetic acid
1mM EDTA
adjusted to pH 8.0
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Separating gel 10-15%
10 - 15% (v/v) acrylamide/bisacrylamide
375mM Tris-Hcl (pH 8.8)
0.1% (w/v) SDS
0.1% (w/v) APS
0.1% (v/v) TEMED
Stacking gel 4%
4% acrylamide/bis-acrylamide
125mM Tris-HCl (pH 6.8)
0.1% (w/v) SDS
0.1% (w/v) APS
0.1% (v/v) TEMED
Sumo buffer A
25mM Tris-HCl (pH 6.8)
20mM imidazole
protease inhibitor cocktail (1:1000, Sigma) and 0.1mM NEM (Sigma) freshly added
Sumo buffer B
6M guanidium hydrochloride
10mM imidazole
in PBS
protease inhibitor cocktail (1:1000, Sigma) and 0.1mM NEM (Sigma) freshly added
TNN lysis buffer
50mM Tris-HCl pH 7.4
120mM NaCl
5mM EDTA
0.5% (v/v) NP40
10mM Na4P2O7
100mM NaF
2mM NaVO4
protease inhibitor cocktail (1:1000, Sigma), freshly added
36 Chapter 2: Materials
trypsin solution
0.25% trypsin
5mM EDTA
22.3mM Tris pH 7.4
125mM NaCl
2.9. Consumables and equipment
Consumables such as reaction tubes, cell culture and other plastic products were purchased
from Applied Biosystems, Eppendorf, Greiner, Kimberley-Clark, Nunc, Sarstedt, B. Braun,
Schleicher und Schüll, Millipore and VWR international.
2.9.1. Equipment
Chemiluminescence imaging
LAS-4000 mini (Fujifilm)
Cell culture incubator
BBD 6220 (Heraeus)
Cell counter
CASY cell counter (Innovatis)
Centrifuges
Galaxy MiniStar (VWR International)
Eppendorf 5417 R (Eppendorf)
Eppendorf 542 (Eppendorf)
Multifuge 1S-R (Heraeus)
Avanti J-26 XP (Beckman Coulter)
Fluorcytometer
BD FACS Canto II (BD Biosciences)
Heating block
Dry Bath System (STARLAB)
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Incubator shaker
Model G25 (New Brunswick Scientific)
Luminometer
GloMax 96 Microplate Luminometer (Promega)
Microscope for immunofluorescence
DMI 6000 B (Leica)
SP5 (Leica)
Microscope for cell culture
Axiovert 40CFL (Zeiss)
PCR thermal cycler
Mastercycler pro S (Eppendorf)
Photometer
UltrospecTM 3100 pro UV/Visible (Amersham Biosciences)
Spectrofluorometer NanoDrop 3000 (Thermo Scientific)
Power supply
PowerPac HC (Bio-Rad)
Quantitation of RNA
Experion Automated Electrophoresis System (Bio-Rad)
StdSens Experion RNA Chip
Quantitative real-time PCR machine
MXp3000P qPCR system (Stratagene)
SDS-PAGE system
Mini-PROTEAN Tetra Cell (Bio-Rad)
Sterile bench
HeraSafe (Heraeus)
38 Chapter 2: Materials
Ultrasonifier
W-250 D (Heinemann)
Universal shaker
SM-30 (Edmund Bühler GmbH)
UV fluorescent table
Maxi UV fluorescent table (PEQLAB)
UV filtered lamp
VL-6.MC with 312nm and 254nm (Vilber Lourmat)
Vortex mixer
Vortex-Genie 2 (Scientific Industries)
Waterbath
ED-5M heating bath (Julabo)
Western blot transfer chamber
Harnischmacher
2.10. Software
Ape plasmid editor
M. Wayne Davis
BD FACSDiva 6.1.2
BD Biosciences
CLC Sequence Viewer 6
CLC bio
DOG visualization of protein domain structures
Lab of Cell Dynamics, Hefei, China
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GraphPad Prism
GraphPad Software
LAS AF 2.0
Leica
MxPro qPCR Software
Stratagene
Multi Gauge
Fujifilm
Papers
Mekentosj
SUMOsp 2.0 SUMOylation sites prediction
Lab of Cell Dynamics, Hefei, China
Mac OS X
Apple Inc.
Illustrator, Photoshop, Acrobat
Adobe Inc.
Windows XP; Excel, Power Point
Microsoft Inc.
TeXniCcenter
BCG Soft Ltd.

Chapter 3.
Methods
3.1. Molecular biology methods
3.1.1. Transfection of bacteria with plasmid DNA and plasmid amplification
Circular DNA can be transformed into bacteria to amplify the plasmid. Competent bacteria
were thawed on ice and mixed with 1 μg plasmid DNA or ligation mix, then incubated on
ice for 30min followed by a one minute heat shock at 42 °C. The bacteria were plated on an
LB agar plate to pick clones from the next day or directly cultivated in 200ml LB medium
to amplify the plasmid on a larger scale. Both procedures were conducted at 37 °C using
the appropriate antibiotic to select for bacteria that had been successfully transformed.
3.1.2. Isolation of plasmid DNA from bacteria
A large scale purification of plasmid DNA was performed with the JETSTAR 2.0 Plasmid
Purification Maxi Kit according to the manufacturer's instructions. The purified plasmid
was dissolved in B. Braun water, diluted to a concentration of 1 μg/μl and stored at -20 °C.
For the isolation of small amounts of plasmid (mini prep), 1.5ml of cultivated bacteria were
transferred to a reaction tube, spun down and resuspended in 200 μl plasmid prep buffer 1
to lyse the cells. After a five minute incubation at room temperature 200 μl plasmid prep
buffer 2 was added to denature the protein components, these were spun down subsequently
(18,000 x g, 5min, 4 °C). The supernatant was vigorously mixed with 200 μl isopropanol to
precipitate the DNA, which was then pelleted through centrifugation (18,000 x g, 10min,
4 °C). The DNA was washed one with 70% Ethanol, then dried and resuspended in 50 μl
B. Braun water.
3.1.3. Nucleid acid quantitation
The concentration of DNA and RNA in solution was determined with Peqlab's NanoDrop
1000. Purity was determined by assessing the ratio of absorbance at 260 and 280 nm. For
pure DNA, A260/280 is ∼ 1.8, for RNA ∼ 2.
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3.1.4. Sequence specific hydrolysis of DNA (restriction digest)
DNA was hydrolyzed in a sequence-specific manner with restriction endonucleases from
Fermentas and New England Biolabs using the recommended reaction buffers. The
digestions were set up according to the table below and incubated at 37 °C for one hour.
Table 3.1.: Restriction digest mix
2 μg DNA
1 μl restriction endonuclease 1
1 μl restriction endonuclease 2 (if applicable)
2 μl 10 x reaction buffer
ad 20 μl aqua bidest.
3.1.5. Separation of DNA fragments via gel electrophoresis
DNA fragments of different sizes were separated by agarose gel electrophoresis. Depending
on the fragment size, a solution of 1-2% agarose was boiled in TAE buffer. 0.3 μg/ml
ethidium bromide was added and the molten agarose was poured into a gel chamber with
combs to form sample wells in the gel. DNA loading buffer was added to the DNA samples
which were then pipetted into the wells of the polymerized agarose gel. The size of the
nucleotide fragments was determined using 1.5 μl of the 1 kb DNA Ladder from Invitrogen
which was separated next to the samples. The gel was run at 120V for one hour, then the
DNA fragments were visualized using a UV transilluminator which detects the intercalator
ethidium bromide.
3.1.6. DNA extraction and purification from agarose gels
After separating the DNA by gel electrophoresis the fragment of interest was cut out of
the gel with a scalpel. The DNA was extracted from the gel using the Gel Extraction Kit
from Qiagen following the manufacturer's protocol.
3.1.7. Ligation of DNA fragments
Double stranded DNA fragments were attached to one another covalently by means of
ligation. Insert and plasmid were incubated in a molar ration of 3 : 1 in the ligation mix
according to the table below and incubated for four hours at RT or o./n. at 16 °C. To
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calculate the optimal amounts of backbone and plasmid the Gibthon ligation calculator
was used (http://www.gibthon.org/ligate.html).
Table 3.2.: Ligation mix
∼ 100 ng linearized plasmid
x ng DNA fragment (insert)
1 μl T4 DNA ligase buffer (Fermentas)
1 μl T4 DNA ligase (Fermentas)
ad 10 μl aqua bidest.
3.1.8. Isolation of RNA
For the isolation of total RNA from cultured cells TriFast reagent from Peqlab was used.
Cells were pelleted by centrifugation (5min, 400 x g, 4 °C), then resuspended in 1ml
TriFast. After five minutes 200 μl chloroform was added and the mixture was vortexed
thoroughly for 15 seconds. After three more minutes of incubation the solution was sep-
arated into aqueous and organic phase by centrifugation (10min, 18,000 x g, 4 °C). The
upper, aqueous phase was transferred into a fresh reaction tube and the RNA was precipi-
tated by adding an equal volume of isopropanol followed by vortexing for 15 seconds. The
samples were frozen at -20 °C for 30 minutes, then centrifuged (10min, 18,000 x g, 4 °C)
and the pellet was washed in 75% Ethanol. The final pellet was dried, then resuspended
in 20 μl B. Braun water, frozen at -20 °C, then thawed again and the RNA concentration
was determined by NanoDrop measurement. The RNA was used for cDNA synthesis and
the remainder stored at -80 °C.
3.1.9. DNAse digestion and cDNA synthesis
To remove any residual traces of DNA from the RNA preparations, a DNAse digestion
was performed on the total RNA isolated from the cells. 2 μg of RNA were diluted in
8 μl of B. Braun water and mixed with 1 μl of 10 x digestion buffer containing MgCl2,
1 μl of RNAse-free DNAse (both from Qiagen) and 0.2 μl of RNAse inhibitor Ribolock
(Fermentas) . This mix was incubated for 30 minutes at 37 °C, then 1 μl of 25mM EDTA
was added and incubated at 65 °C for 10 minutes to stop the digestion.
To quantify specific mRNAs, the RNA was then transcribed into complementary DNA
(cDNA) by reverse transcription, using random hexanucleotide primers. For that, 2 μg
total RNA in a volume of 10 μl were heated up to 65 °C to dissolve any secondary
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structures. The cDNA synthesis mix according to the table below was added and
incubated for 10min at RT, 50min at 37 °C and 15min at 70 °C. The generated cDNA
was used for qRT PCR and stored at -80 °C.
Table 3.3.: cDNA synthesis mix
10 μl 5 x First Strand Buffer (Invitrogen)
5 μl dNTPs (2.5 mM, Roth)
2 μl random primer p(dN)6 (2 μg/ml)
0.2 μl Ribolock (Fermentas)
1 μl M-MLV reverse transcriptase (200U/μl, Promega)
ad 40 μl B. Braun water
3.1.10. Polymerase chain reaction (PCR)
The polymerase chain reaction [Mullis et al., 1992] was used to amplify specific regions of
nucleic acids for different purposes as described below.
PCR to amplify cDNA for cloning
To generate new expression vectors the gene of interest was amplified based on existing
expression vectors, which allowed for the addition of new restriction sites.
Table 3.4.: Standard PCR setup
5 μl 10 x Pfu buffer (Stratagene)
1 μl Pfu polymerase (Stratagene)
100 ng cDNA template
10 pmol forward primer
10 pmol reverse primer
1 μl DMSO
1 μl dNTPs (10mM)
ad 50 μl B. Braun water
PCR based site directed mutagenesis
To mutate single bases in a PCR template primers were chosen as such to fit the desired
target sequence. As such, a product mostly containing the modified bases was generated.
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Table 3.5.: Standard PCR thermal cycling profile
temperature time
95 °C 3min
95 °C 30 sec
53 - 65 °C (template dependent) 60 sec
 30 cycles
68 °C 3min
72 °C 10min
To remove residual wild type template DNA, the PCR product was digested with the
enzyme DpnI (1 h, 37 °C), which hydrolyses only methylated DNA.
Table 3.6.: Mutagenesis PCR setup
5 μl 10 x Phusion buffer (Fermentas)
1 μl Phusion High Fidelity Polymerase (Fermentas)
100 ng cDNA template
0.25 pmol forward primer
0.25 pmol reverse primer
0-5 μl DMSO
1 μl dNTPs (10mM)
ad 50 μl B. Braun water
Table 3.7.: Mutagenesis PCR thermal cycling profile
temperature time
98 °C 1min
98 °C 30 sec
55 °C 60 sec
 16 cycles
72 °C 2min
72 °C 10min
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Quantitative reverse transcriptase PCR (qRT PCR)
To quantify specific mRNA levels the cDNA synthesized by reverse transcription was am-
plified by real time PCR. The qPCR SYBR Green Mix from Thermo Scientific was used
to set up a reaction mix as described in the table below, and pipetted into the wells of
96-well qPCR plates. Finally, 10 μl of a 1:10 dilution of cDNA was added to each well, the
measurement was carried out with the Mx3000P qPCR system (Stratagene).
Table 3.8.: qRT PCR setup
5 μl SYBR Green Mix (Thermo Scientific)
1 μl 1 μl forward primer (10 pmol/ μl)
1 μl 1 μl reverse primer (10 pmol/ μl)
ad 10 μl B. Braun water
10 μl cDNA in a 1:10 dilution added to the respective wells
Table 3.9.: qRT PCR thermal cycling profile
temperature time
95 °C 15min
95 °C 30 sec
60 °C (template dependent) 20 sec
 38 cycles
72 °C 15 sec
95 °C 1min
60 °C 30 sec
95 °C 30 sec
The basis of real time PCR is fluorescent monitoring of DNA amplification, from which
target DNA concentration can be determined from the fractional cycle at which a threshold
amount of amplicon DNA is produced. The calculation was performed using the relative CT
method (Applied Biosystems User Bulletin 2); the housekeeping gene beta-2-microglobulin
was used for normalization. The measurements were performed in triplicates to calculate
the standard deviation according to the Gaussian law of error.
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3.1.11. Microarray
RNA for a genome-wide microarray analysis was extracted from cells using the RNeasy
Mini Kit (Qiagen). The quality and quantity of the RNA were examined using the Expe-
rion Automated Electrophoresis System with a StdSens Experion RNA Chip (Bio-Rad).
Total RNA was labeled with the Quick Amp Labeling Kit (2-Color; Agilent). Agilent
SurePrint G3 Human GE 8x60K Microarray (Agilent; Design ID: 028004) was used for
the analysis of the gene expression of the different samples in a reference design assay.
The reference was generated as a pool of all samples to be analyzed. This reference probe
was labeled with Cy3 dye, whereas the samples were labeled with Cy5 dye. After a 17 h
hybridization at 65 °C, slides were washed according to the manufacturer's instructions
and subsequently scanned using an Agilent DNA microarray scanner G2505C (scan
software: Agilent Scan Control version A.8.1.3; quantification software: Agilent Feature
Extraction version 10.5.1.1, FE Protocol GE2_105_Dec08).
The resulting intensity values for the red and green channels were normalized using the
lowess method within the limma package in R/BioConductor. Regulated probes were
selected on the basis that the logarithmic (base 2) average intensity value (A-Value) was
≥5. A threshold to indicate probes as differentially expressed between two samples (M-
Value) was set at 2-fold change (log2(M) ≥1).
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3.2. Cell biology methods
All cell culture work was performed at a sterile workbench. Cells were cultivated in CO2
incubators at 37 °C, 95% relative humidity and 5% CO2.
3.2.1. Passaging of cells
Adherent cells were passaged before completely covering the surface to avoid contact in-
hibition of growth. The cultivation medium was removed and the cells were washed with
PBS. An appropriate amount of trypsin solution was added (e.g. 1ml on a 10 cm dish)
and incubated for 5 minutes at 37 °C to detach the cells. By resuspending the cells in fresh
medium the enzymatic activity of trypsin was stopped and a single cell solution was gen-
erated. For S2 cells the cell count was determined with a Neubauer counting chamber, for
S1 cells with the CASY cell counter. The cells were then seeded for experiments according
to their size and proliferation rate in relation to the length of the experiment.
3.2.2. Freezing and thawing cells
For long-term freezer storage cells were detached with trypsin solution as described above,
resuspended in fresh medium and then pelleted (5min, 400 x g, 4 °C). The cells were
resuspended in 1ml freezing medium containing DMSO, transferred to a cryo vial and
then slowly frozen at -80 °C using a MrFROSTY freezing container. After 24 h the cells
were stored in a liquid nitrogen storage tank.
To unfreeze cells stored in cryo vials these were quickly heated up in a 37 °C water bath,
then transfered onto a 10 cm dish containing 10ml fresh medium. After the cells had
attached to the dish the medium was replaced to remove all traces of DMSO.
3.2.3. Transfection of plasmid DNA
To transfect mammalian cells with plasmid DNA one of the following transfection methods
was used, depending on the transfection efficiency in different cell lines. An expression of
the transiently transfected DNA was observed mostly already after 24 h.
Calcium phosphate transfection
Cells were seeded 24 h before transfection. For 10 cm dishes, 500 μl transfection mix was
prepared according to the table below, for dishes with a lower or higher surface area the
total volume of transfection agent was scaled appropriately. The transfection mix was
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incubated for 5 minutes at RT, then 500 μl 2 x HBS was added dropwise while vortexing
to generate calcium phosphate DNA complexes, which were then immediately added to
the cells. 12-16 h later the remaining DNA precipitates were removed by washing the cells
with PBS upon which fresh medium was added.
Table 3.10.: Transfection mix
5-20 μg plasmid DNA
50 μl CaCl2 (2.5 M)
ad 500 μl B. Braun water
Polyethylenimine (PEI) transfection
Cells were seeded 24 h before transfection in their usual cultivation medium. 5 h before
the actual transfection process the basal medium was replaced by transfection medium
containing only 2% FCS and no antibiotics. A transfection mix containing 5-15 μg plasmid
DNA and 500 μl PBS as well as 10-30 μl PEI in 500 μl PBS were each set up to incubate
5min at RT. Then the PEI/PBS solution was added to the DNA mix to incubate another
20 minutes at the same conditions before dropping it onto the cells. 4 h later the remaining
DNA precipitates were removed by washing the cells with PBS upon which fresh medium
was added.
3.2.4. Transfection of siRNA
For the transfection of synthetic siRNAs cells were seeded at high density in 6 cm dishes
using antibiotic-free medium. 24 hours later 5 μl siRNA (20 μg) was diluted with Opti-
MEM I (Invitrogen) to 500 μl. 10 μl of of the lipid transfection reagent Lipofectamine
RNAiMAX (Invitrogen) was likewise diluted with Opti-MEM I to a volume of 500 μl. RNA
and transfection solution were mixed to incubate for 20min at RT, then dropped onto the
cells, leading to a final concentration of 20 nM siRNA and 0,2% RNAiMAX. 12-16 h later
the cells were provided with fresh medium.
3.2.5. Infection of mammalian cells
Cells were infected to stably integrate plasmid DNA into the genome of target cells.
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Infection with retrovirus
For infection with retrovirus the moloney murine leukaemia virus (Mo-MuLV) was gener-
ated, which infects a range of hosts including mice. The packaging cell line Phoenix-Eco
was used to generate this recombinant retrovirus. Phoenix cells originate from HEK 293T
cells and express the viral gene fragments gag, env and pol. To infect human cell lines
these were transfected with the murine ecotrophic receptor beforehand.
Phoenix cells were seeded at a high density to be transfected 24 h later. The calcium
phosphate method was used to transfect the cells with retroviral expression vectors
such as pBABE. 15 h later, the cells were provided with a low amount of fresh medium
concentrating the virus released by the cells into the supernatant. The virus supernatant
was harvested in 15ml falcons after approximately 40 and 64 h and filtered with a syringe
and 45 μm sterile filter (Sarstedt) to remove residual Phoenix cells. The virus was then
snap-frozen in liquid nitrogen to be stored at -80 °C.
Target cells to be infected were seeded 24 h prior to infection. The virus supernatant was
thawed quickly in the 37 °C waterbath. For 10 cm dishes the old medium was removed,
5ml of virus supernatant were supplemented with 3ml fresh medium and added to the
cells. To increase the infection efficiency, 5 μl of the cationic polymer polybrene (4 μg/μl
hexadimethrin bromide) was added as well. The supernatant was exchanged 12-16 h later
for complete medium. To select for successfully transfected cells antibiotics were added
48 h after infection, comparing infected with uninfected cells to determine the completion
of the selection process.
Infection with lentivirus
Lentivirus can very efficiently mediate integration of transgenes in dividing and unlike
retrovirus also in nondividing cells. HEK 293T cells were used to generate lentivector
particles by transfecting them with separate plasmids coding for the virion packaging
system, the envelope, and the gene of interest. The structural and enzymatic components
of the virion came from HIV-1, the envelope from vesicular stomatitis virus (VSV), using
a second generation LV packaging system.
HEK 293T cells were seeded at a high density. 24 h later the cells were transfected with
the packaging vector psPAX.2, the envelope vector pMD2G and the gene of interest in an
appropriate vector, such as pRRL. 15 h later, the cells were provided with a low amount
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of fresh medium concentrating the virus released by the cells into the supernatant. The
virus supernatant was harvested in 15ml falcons after approximately 40 and 64 h and
filtered with a syringe and 45 μm sterile filter (Sarstedt) to remove residual Phoenix cells.
The virus was frozen at -80 °C for storage.
3.2.6. Colony Assay
The proliferation behavior of cells was determined by colony assay. Cells were infected with
different genes of interest and a control and selected with antibiotics if necessary. After
selection, the cells from each condition were counted and a defined number was seeded on
6 cm dishes using medium without the selection agent. The cells were grown for six to
seven days without allowing them to become confluent. To visualize the colonies cells were
washed with PBS, then stained with the triphenylmethan dye crystal violet for at least
1 h. The superfluous dye was washed away with desalted water and the cell culture dishes
were dried at room temperature.
3.2.7. Propidium iodide staining for flow cytometry (PI FACS)
Flow cytometry or FACS (fluorescence activated cell sorting) was used to analyze cells
based on detection of a fluorescent intercalating agent. The cell cycle stage was determined
by measuring fluorescence emission of the intercalating dye propidiumiodide (PI), which
relates to the DNA content as follows: G0/G1 (2N), S (>2N, <4N) and G2/M (4N).
Polyploid cells (>4N) and apoptotic or necrotic cells (subG1, <2N) could thus be identified
as well.
Cells were harvested by trypsinisation including floating cells from the medium su-
pernatant. After resuspension in 1ml cold PBS the cells were fixed by adding 4ml ice-cold
absolute ethanol while vortexing. The cells were stored at least one night at -20 °C, then
washed with PBS and resuspended in FACS buffer containing propidium iodide solution.
After at least 1 h of staining in the dark at RT the cells were transferred into FACS
tubes and measured with the BD FACSCanto II with the following measurement settings:
excitation wavelength of 488nm using a 556 nm longpass- and a 585/42 nm bandpassfilter
for propidium idodide (emission at 617 nm). The cell cycle distribution was analysed
using the BD FACSDiva 6.1.2 software.
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3.3. Protein biochemistry methods
3.3.1. Generation of protein lysates for Western blot
To isolate total protein cells were washed in ice cold PBS, scraped off the cell culture dish
and pelleted (400 x g, 5min, 4 °C). The cell pellet was either frozen in liquid nitrogen to
be stored at -80 °C or directly subjected to lysis by resuspending cells in TNN-, NP40- or
RIPA-buffer with freshly added proteinase inhibitors (1:1000). The cells were incubated
for 30 minutes on ice, then the cell debris was pelleted (18,000 x g, 10min, 4 °C) and the
supernatant transferred to a fresh tube. The protein concentration was determined and
the lysate stored at -80 °C until further use.
Alternatively, cells grown in 24- or 6-well plates were lysed directly in hot SDS sample
buffer, transferred to a reaction tube and boiled for 15 minutes. The lysates were then
used for Western blot analysis or stored at -20 °C.
3.3.2. Protein determination by the Bradford method
Protein concentrations were determined according to Bradford [1976]. 500 μl H2O was
pipetted into Semi-Micro Cells, 1 μl of the protein sample solution was added and mixed
with 500 μl Quick Start Bradford dye reagent (Bio-Rad). After an incubation time of
5min at RT the absorption was measured at a wavelength of 595 nm using an appropriate
reference. The measured values were compared to a previously obtained standard curve to
calculate the protein concentration of the sample solution.
3.3.3. SDS polyacrylamide gel electrophoresis (SDS-PAGE)
Discontinuous SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel electrophoresis) was
used to separate proteins according to size [Laemmli et al., 1970]. Protein lysates as
described in 3.3.1 were filled up with lysis buffer to an equal volume, then mixed with
half the volume of 3 x SDS sample buffer. These samples were incubated 5 minutes at
95 °C and spun down afterwards, as were eluates of immunoprecipitations, sumoylation
and ubiquitination assays or samples obtained by direct SDS lysis. The protein samples
were then transferred into the wells of an SDS polyacrylamide gel consisting of a 7.5-
15% stacking gel and a 4% resolving gel. The PageRuler Pre-Stained Protein Ladder
(Fermentas) was used as a size marker. The electrophoresis was carried out using the
Bio-Rad SDS-PAGE chamber with SDS running buffer, first at 80V for 30 minutes, then
at 120V for 90 minutes.
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3.3.4. Staining Protein gels with Coomassie Blue
To visualize proteins obtained by recombinant expression (3.3.9) these were subjected to
SDS-PAGE, the gel was then stained in coomassie solution for at least 1 h. To remove
excess dye the gel was incubated in destaining solution with gentle shaking until a clear
background was obtained.
3.3.5. Western blot
Proteins were separated by SDS-PAGE (3.3.3), followed by electroblotting onto a PVDF
membrane using a tank blot system. A PVDF membrane the size of the SDS gel was
incubated first in methanol for 1min, then washed in desalted water for 2min and finally
equilibrated in tank blot buffer for another 2min. Gel and membrane were neatly layered
on top of each other and fixed between Whatman filter papers in a Western blot trans-
fer chamber (Harnischmacher). The electrophoretic protein transfer was carried out at
250mA for 3 h. All following incubation steps were performed with gentle shaking. The
membrane with immobilized proteins was blocked in blocking solution for at least 30min,
then cut into pieces if several proteins from the same membrane were to be visualized. The
membrane pieces were incubated o./n. with a dilution of primary antibody in blocking
solution, then washed (3 x 10min in TBS-T), incubated with secondary antibody in block-
ing solution for 1 h at RT, then again washed (3 x 10min in TBS-T). Finally, the proteins
of interest were visualized via chemiluminescence, induced by the horseradish peroxidase
coupled to the secondary antibody. To trigger a specific chemiluminescent signal the Im-
mobilon Western Chemiluminescent HRP Substrate from Millipore was used according to
the manufacturer's instructions, the signal was detected with the ImageQuant LAS 400
imager (Fujifilm Global).
3.3.6. Stripping antibodies from PVDF membranes
To release antibodies from a PVDF membrane covered with immobilized proteins the mem-
brane was incubated in stripping buffer for 30min in a 60 °C water bath. The membrane
was washed, blocked and incubated with primary and secondary antibodies as described
in 3.3.5.
3.3.7. Immunoprecipitation
Immunoprecipitations (IPs) were performed to detect protein-protein interactions. Cells
were lysed in TNN lysis buffer with fresh proteinase inhibitors (1:1000) and sonicated
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(4 x 5 sec, 1min pause, 20%) using the W-250 D sonifier (Heinemann). The lysate was
centrifuged (10min, 18,000 x g, 4 °C) to spin down the cell debris, the supernatant was
transferred to a fresh tube. The protein concentration was determined as described in
3.3.2, the same amount of protein was used in each IP condition, filling up samples with
TNN buffer to a volume of 400 μl as needed. A 5% input of each lysate was collected and
boiled with SDS sample buffer. For preclearing, 40 μl of 10% BSA in TNN was added
to each 400 μl sample, as well as 50 μl of a mixture of washed protein A/G sepharose
beads (Protein A Sepharose CL-4B from Invitrogen, Protein G Sepharose Fast Flow from
Sigma). The samples were incubated on a rotating wheel for 4 h at 4 °C, then the beads
were spun down and discarded. 2 μg of specific antibody was added to each IP sample and
these were rotated o./n. at 4 °C. The next day 50 μl fresh protein A/G sepharose beads
ware added to the IP samples to incubate on a rotating wheel for 2 h. The beads loaded
with protein-bound antibodies were washed four times with TNN buffer, then 40 μl of SDS
sample buffer were added to elute the protein at 95 °C for 5min and the samples were
subjected to SDS-PAGE and Western blot using the input as a reference for IP efficiency .
3.3.8. In vivo sumoylation assay
To detect if a protein of interest could be modified by Sumo in vivo cells were transfected
with plasmids expressing His-tagged Sumo and the protein of interest. The cells were
harvested 48 h after transfection, 10% of each sample was collected separately and boiled
in SDS sample buffer to be used as an input. The remaining cells were lysed in 1ml
Sumo buffer A containing proteinase inhibitors and freshly prepared NEM. To completely
disrupt the cells these were sonicated (4 x 5 sec, 10 sec pause, 20%) and cleared of the cell
debris by centrifugation (10min, 6000 x g, 4 °C). The supernatant was transferred to a
fresh tube, 100 μl of a 50% slurry of previously washed Ni2+-NTA-agarose were added and
incubated on a rotating wheel o./n. at 4 °C. The next day the beads were spun down by
centrifugation (2min, 1000 x g, 4 °C) and washed two times with 1ml Sumo buffer A, two
times with a 1:4 mixture of buffer A and B, and two times with Sumo buffer B. To elute
sumoylated proteins from the beads these were boiled in 100 μl of SDS sample buffer for
5min and centrifuged (1min, 1,000 x g). The supernatant was subjected to SDS-PAGE
and Western blot side by side with the input sample.
3.3.9. Bacterial expression and purification of GST fusion proteins
The gene of interest was cloned into a pGEX expression vector to enable expression of a
GST fusion protein in E.cli BL21 cells, which perform high-efficiency protein expression
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upon induction by IPTG. The transfection and cultivation of bacteria was performed as
described in 3.1.1 A clonal overnight culture of BL21 containing the pGEX construct was
diluted 1:20 and incubated shaking at 25 °C. As soon as the culture reached an optical
density of A600nm=0.6 IPTG (isopropyl-β-D-thiogalactopyranoside) was added to a final
concentration of 1mM to induce expression of the GST fusion protein. The culture was
grown for another 6 h before pelleting of the bacteria (7.700 x g, 10min, 4 °C), which were
either stored at -80 °C or directly subjected to lysis. To lyse the cells 100ml of bacterial
culture were resuspended in 2ml bacterial lysis buffer with fresh proteinase inhibitors, then
sonicated (10 x 10 sec, 1min pause, 40%). The lysate was centrifuged at high speed (10,000
x g, 20min, 4 °C) to pellet the bacterial cell debris and insoluble protein, this pellet was
solubilized in 2ml bacterial wash buffer. A fraction of each the solubilized pellet and the
supernatant was mixed with SDS sample buffer and analyzed on a coomassie gel to verify
the expression of the GST fusion protein and determine its solubility.
3.3.10. GST pulldown
To analyze the interaction of in vitro translated proteins with recombinant GST tagged
Sumo a GST pulldown experiment was performed. GST-Sumo1, 2 and 3 were expressed
and purified according to 3.3.9. 300 μl of a 50% slurry of glutathion sepharose beads were
washed in 10ml PBS/ 1% Triton X-100 and added to each GST-Sumo lysate to be incu-
bated for two hours at 4 °C on a rotating wheel. The beads were washed three times with
10ml PBS/ 1% Triton X-100 and then resuspended in 150 μl PBS. 2 μl of the beads in
PBS were boiled in 200 μl SDS loading buffer for 5min and analyzed via SDS-PAGE and
coomassie gel to quantify the fraction of glutathion-bound Sumo1, 2 and 3. The remaining
beads were spun down (1min, 200 x g, 4 °C), resuspended in glycerine and stored at -20 °C.
For the in vitro transcription and translation the TNT Quick Coupled Trancription/Trans-
lation System from Promega was used according to the manufacturers instructions with
twice the recommended amount of plasmid and kit reagents. The DNA template origi-
nated from pcDNA3 expression plasmids with T7 RNA polymerase promoter. From the
in vitro translated samples 2% were kept as an input and boiled in SDS sample buffer,
the remainder divided into four reaction tubes and diluted to 500 μl with GST binding
buffer. Equal volumes of GST only, GST-Sumo1, 2 and 3 bound to the sepharose beads
were added according to the quantification from the coomassie gel and incubated rotating
for 4 h at 4 °C. The beads were washed five times with each 1ml of GST washing buffer,
then boiled in 20 μl SDS sample buffer and centrifuged (3min, 1,000 x g). Finally, the
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supernatant from the beads and the 2% input was analyzed via SDS-PAGE and Western
blot.
3.3.11. Indirect immunofluorescence
Cells were cultivated and transfected on cover slips to be processed for indirect immunoflu-
orescence. To fix the cells they were incubated in 3.7% paraformaldehyde for 15min at
RT after an initial wash with ice-cold PBS. To permeabilized the cells they were washed
with PBS/ 0.1M Glycin (3x 10min, RT) and PBS/ 0.1% NP-40 (3x 10min, RT), to be
blocked with PBS/ 0.5% NP-40/ 5% FCS (blocking buffer) for 45min at 37 °C. The cover
slips were transferred into a wet chamber with the cells facing upwards and 40 μl of pri-
mary antibody diluted in blocking buffer was pipetted on top. After an incubation time of
45min at 37 °C the cells were washed three times with blocking buffer. Next the cells were
incubated with a 40 μl dilution of secondary antibody (1:400) and Hoechst nuclear stain
(1:5000) in blocking solution, again for 45min at 37 °C in the dark. Unbound antibody was
removed by washing three times with blocking buffer. Finally the cover slips were washed
with distilled water and mounted on a glass slide using a small drop of mounting medium,
the slides could be stored in the dark at 4 °C before analyzing them with the fluorescence
microscope. Confocal images were obtained as described in detail in Herkert et al. [2010].
3.3.12. Luciferase reporter gene assay
Cells in 6-well plates were transfected with reporter constructs and additional expression
plasmids. 24 h later, the cells were washed with ice cold PBS and disrupted in 250 μl passive
lysis buffer (Promega) for 15min at RT while shaking. The lysate was transferred into a
reaction tube and cleared of the cell debris by centrifugation (1min, 400 x g, 4 °C). To
determine the luciferase activity, 50 μl of lysate was pipetted into a clear bottom 96-well
plate and placed into the Glomax 96 Microplate Luminometer. The device automatically
added 100 μl of freshly prepared luciferase substrate solution and measured light emission
at 562 nm two seconds later for an interval of ten seconds (in relative light units, RLU).
To normalize the obtained values the protein concentration was determined as described
in 3.3.2.
3.3.13. UV treatment of cells
Before irradiation of attached cells, the medium supernatant was completely removed, the
cells were irradiated for 60 seconds after which the very same medium was restored. Cells
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on 6 cm or 10 cm dishes were treated with a dose of 500 J/m2 UV-B all at the same time
and then harvested at different time points by trypsiniation, including floating cells in the
medium supernatant.

Chapter 4.
Results
4.1. The tumor suppressor Arf interacts with Miz1 to antagonize
its function
4.1.1. Miz1 recruits Arf into the nucleoplasm and is itself sequestered into
subnuclear foci
Nucleophosmin (NPM) has been identified as an essential coactivator of Miz1 [Wanzel
et al., 2008]. In unstressed cells, the majority of NPM resides in the nucleolus, but it
also shuttles into the nucleoplasm and cytoplasm [Yu et al., 2006]. NPM accumulates in
the nucleoplasm upon induction of stress such as DNA damage and also upon expression
of Miz1 [Wanzel et al., 2008]. In the nucleolus NPM acts as a chaperone for the tumor
suppressor protein Arf [Bertwistle et al., 2004] and Arf is known to interact with Myc [Qi
et al., 2004]. Since both NPM and Myc are binding partners of Miz1 it was investigated
if there was also an interaction between Miz1 and Arf.
Expression of Miz1 in HeLa cells recruited endogenous and overexpressed p14Arf out of the
nucleoli into the nucleoplasm (Fig. 4.1 A). The intranuclear distribution of Miz1 markedly
changed from a homogenous distribution to an accumulation in subnuclear structures in
about 80% of all transfected cells. These foci partially overlapped with the nucleoplasmic
Arf, indicated by a Pearson's correlation coefficient (Rr) of 0.519 as a mean value of ≥ 5
cells. The Pearson correlation describes similarity between shapes to indicate colocaliza-
tion; 1.0 indicates perfect positive correlation, -1.0 complete negative correlation [Zinchuk
et al., 2007].
4.1.2. Arf and Miz1 associate with each other
To determine if Arf binds to Miz1, immunoprecipitation assays were conducted, the results
of which are summarized in Figure 4.2. It could be shown that both human p14Arf as well
as mouse p19Arf bind to Miz1 in vivo [Herkert et al., 2010]. This interaction is independent
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Figure 4.1.:
Miz1 recruits endogenous and exogenous Arf into the nucleoplasm and is itself sequestered into
subnuclear structures 1
A.-B. HeLa cells grown on cover slips were transfected with expression plasmids for Miz1 and p14Arf and fixed
for immunofluorescence 48 h later. Miz1 and p14Arf proteins were detected with specific antibodies,
Hoechst 33258 was used to stain chromatin. The Pearson correlation coefficient was calculated as a
mean value of ≥ 5 cells.
C. The localization of Miz1, either homogeneously distributed in the nucleus and/or cytoplasm or in het-
erogenous subnuclear foci was quantified counting ≥ 40 transfected cells.
1 These Figures were published in similar form in Herkert et al. [2010] (see also following pages).
of nucleophosmin, as it is still valid in NPM-/- MEFs. On the contrary, enforced expression
of NPM in these cells severely impaired the interaction between Miz1 and Arf. Myc both
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binds to Miz1 and Arf but does not simply act as a scaffold for the association of Miz1
and Arf, as Myc and Miz1 bind to Arf in different regions (see 4.1.7 on page 64).
Figure 4.2.:
Arf directly interacts with Miz1 which is antagonized by nucleophosmin
Immunoprecipitation experiments in Herkert et al. [2010] showed the previously known interactions
between Myc/Arf, Myc/Miz1, Arf/NPM and Miz1/NPM (grey arrows). In addition, a direct interaction
between Miz1 and Arf which is not dependent on Myc or NPM was discovered (black arrow).
4.1.3. Arf reduces the solubility of Miz1
Verification of Miz1 and Arf protein expression showed that Arf markedly decreased Miz1
levels that could be detected via Western Blot. This occurred using lysis buffers containing
low salt concentrations and relatively mild detergents such as NP-40. This effect could be
ascribed neither to an influence of Arf coexpression on the Miz1 expressing vector nor an
Arf-induced proteasomal degradation of Miz1 [Wanzel, 2010]. In fact, lysing cells in sample
buffer containing 6% SDS at 95 °C revealed that Arf merely reduced the solubility of Miz1,
which could be retained with harsher lysis conditions (Fig. 4.3).
4.1.4. Nucleophosmin inhibits the Arf-induced foci formation and solubility
change of Miz1
To activate transcription, Miz1 forms a soluble complex with its coactivator nucleophosmin
[Wanzel et al., 2008]. Myc competes with NPM for association to Miz1 and induces a less
soluble repressive complex [Peukert et al., 1997]. As elevated expression of nucleophosmin
inhibits the binding of Arf to Miz1 (see 4.1.2 on page 59), I analyzed the effect of NPM on
subnuclear localization and solubility of Miz1. I could reproduce in immunofluorescence
assays that Miz1 recruits nucleophosmin out of the nucleoli into the nucleoplasm as shown
in Wanzel et al. [2008]. Strikingly, elevated expression of NPM completely abrogated the
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Figure 4.3.:
Arf markedly reduces the solubility of Miz11
HeLa cells were transfected with the indicated plasmids and harvested 24 h later using different lysis
conditions, from a mild lysis in NP-40 containing buffers over a harsh lysis in RIPA buffer to a complete
lysis in boiling SDS sample buffer. The protein extracts were analyzed by Western Blot, Cdk2 was used
as a loading control.
formation of subnuclear structures upon expression of Miz1 and Arf (Fig. 4.4 A). Likewise
the Arf-induced solubility change of Miz1 was abolished entirely (Fig. 4.4 B).
4.1.5. Arf inhibits transactivation by Miz1
To analyze the functional outcome of the interaction between Miz1 and Arf I performed
luciferase reporter assays. As seen in previous studies, Miz1 induced the expression of
a P15INK4B promoter plasmid [Staller et al., 2001]. Arf alone did not influence the
basal reporter activity, however it severely inhibited Miz1-dependent transactivation in
a dose-dependent manner (Fig. 4.5). I obtained concurrent results using a P21CIP1
reporter construct (data not shown).
4.1.6. Arf induces sumoylation of Miz1
Arf is primarily know for its function in stabilizing the tumor suppressor p53. More re-
cently also p53-independent functions of Arf have been described, for example its ability
to induce sumoylation of proteins to which it binds, such as NPM and Mdm2 [Tago et al.,
2005]. Interestingly, sumoylation of transcription factors has often been linked to the es-
tablishment of repressive heterochromatic complexes on the DNA [Garcia-Dominguez and
Reyes, 2009].
I therefore aimed to investigate if sumoylation might be involved in the Arf-mediated
effects on Miz1. The immunofluorescence analysis showed that Flag-tagged Sumo2 indeed
colocalized with the Arf-induced Miz1 foci to an exceptional degree (Fig. 4.6 A, Rr =
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Figure 4.4.:
Nucleophosmin inhibits Arf-induced foci formation and solubility change of Miz1 1
A. Immunofluorescence was performed as described in Fig. 4.1, HA-tagged NPM was detected with an HA
antibody.
B. HeLa cells were transfected with the indicated plasmids and harvested 24 h later using a low salt lysis
buffer (containing NP-40 and 150mM NaCl). The protein extracts were analyzed by Western Blot, Cdk2
was used as a loading control.
0.903). To examine if Arf induced the sumoylation of its binding partner Miz1, we set
up an in vitro sumoylation assay. His-tagged Sumo2 in addition to Miz1 and p14Arf
was expressed in HeLa cells and sumoylated protein species were pulled down using Ni2+-
NTA-agarose. Subsequent Western Blot analysis revealed that Miz1 is sumoylated upon
His-Sumo2 expression, which is increased quite significantly by Arf (Fig. 4.6 B, further
results in 4.2.1 on page 70). Next I analyzed if sumoylation is the cause for the formation
of intranuclear Miz1 foci upon Arf expression. In addition to expressing Miz1, Arf and
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Figure 4.5.:
Arf inhibits Miz1-dependent transactivation of the P15INK4B promoter 1
HeLa cells were transfected with the indicated plasmids and a luciferase reporter construct containing
the P15INK4B promotor. 48 h after transfection the specific luciferase activity was determined and
normalized to the protein content in each condition. Immunoblots after SDS sample buffer lysis document
the expression of transfected proteins, β-Actin was used as a loading control. Error bars represent standard
deviation of biological triplicates.
Flag-Sumo2 I depleted the Sumo E2 enzyme Ubc9 for immunofluorescence experiments
using siRNA. Depletion of Ubc9 as the only E2 enzyme in the sumoylation cascade has
been shown to effectively disrupt the cellular sumoylation machinery [Lin et al., 2003].
However, this did not abolish the sequestration of Miz1 into intranuclear structures, but
merely suppressed the colocalisation of Sumo2 in those (Fig. 4.6 C). Furthermore we could
show that the change in solubility by Miz1 through Arf was also not abrogated upon
depletion of the sumoylation machinery [Herkert, 2010]. Taken together, the sumoylation
of Miz1 shows every sign of being independent of the foci formation and solubility change.
4.1.7. An Arf domain binding to Myc is necessary for the effects of Arf on Miz1
Myc is a potent repressor for Miz1 transactivation, inhibits the binding of Miz1 to NPM
and induces a complex of Miz1 and Myc which is resistant to mild extraction [Peukert
et al., 1997; Wanzel et al., 2008].
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Figure 4.6.:
Arf recruits Sumo2 into Miz1 foci and induces the sumoylation of Miz1 1
A. Immunofluorescence was performed as described in Figure 4.1, Flag-Sumo2 was detected with a Flag
antibody.
B. HeLa cells were transfected with the indicated plasmids and harvested 24 h later under denaturing condi-
tions. His-Sumo modified proteins were pulled down using Ni2+-NTA-agarose and analyzed via Western
Blot with a 7.5% input sample.
C. HeLa cells were first transfected with a combination of four siRNAs directed against Ubc9 or a control
siRNA, 24 h later with the indicated protein expression plasmids. Immunofluorescence was performed
another 24 h later as described in Figure 4.1. Protein depletion of Ubc9 was verified by Western Blot
using Cdk2 as a loading control.
Arf also binds to both Miz1 and Arf which is further explained in 4.1.2 on page 59. There-
fore, the Arf-mediated effects on Miz1 might reflect an assembly of the Myc-Miz1 complex.
To further investigate this notion we examined wether Miz1 and Myc interact with Arf
in different regions using Arf deletion mutants. We could reproduced, that c-Myc inter-
acts with the N-terminus of Arf [Qi et al., 2004]. In contrast, Miz1 still binds to an Arf
mutant devoid of the first 65 amino acids. Even though the C-terminal part of p14Arf is
sufficient for the interaction with Miz1, this mutant cannot repress the transactivation, in-
duce the sequestration into less soluble complexes (summarized in Figure 4.7 A) or induce
the sumoylation of Miz1 (Fig. 4.7 B). Immunofluorescence showed that the GFP-tagged
66 Chapter 4: Results
Figure 4.7.:
The N-terminal half of Arf mediates the effects of Arf on Miz1 1
A. The diagram summarizes findings from Herkert et al. [2010] and B: The N-terminal, Myc-binding domain
of Arf is needed to mediate repression, sequestration and sumoylation of Miz1.
B. His-Sumo2 pulldown was performed as described in 4.6 B. The weaker sumoylation signal might be
ascribed to the comparably large GFP-tag fused to the Arf protein.
C. Immunofluorescence was performed as described in Figure 4.1, except that the fluorescence signal was
emitted directly from the GFP-tagged Arf proteins.
N-terminal deletion mutant of p14Arf used for the analysis localizes to the nucleoli to a
similar extent as wild type GFP-p14Arf (Fig. 4.7 C).
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4.1.8. A Myc mutant that cannot bind to Miz1 fails to colocalize in Arf-induced
Miz1 foci
Immunofluorescence analysis expressing c-Myc in addition to Miz1 and p14Arf provides
further evidence for an involvement of Myc as part of the complex. Wild type c-Myc
recruits Arf out of the nucleoli into the nucleoplasm very much like Miz1. More importantly,
c-Myc also colocalizes significantly in Arf-induced Miz1 foci (Fig. 4.8 A) with a Pearsons
correlation coefficient of Rr = 0.848.
Figure 4.8.:
Myc V394D which cannot bind to Miz1 fails to colocalize in Arf-induced Miz1 foci 1
A.-B. Immunofluorescence was performed as described in Figure 4.1. Enforced expression of c-Myc wild type
and c-Myc VD in each case dominated the immunofluorescence signal over endogenous wild type c-Myc.
Furthermore I analyzed the c-Myc V394D mutant, which can no longer bind to Miz1
[Herold et al., 2002], in this context. Myc VD largely fails to colocalize to the Arf-induced
subnuclear structures of Miz1 (Fig. 4.8 B; Rr= 0.360). Please note that enforced expression
of c-Myc wild type and MycVD in each case dominated the immunofluorescence signal,
however endogenous Myc also colocalizes to the Miz1 foci (data not shown).
4.1.9. Miz1 mutants show that the Arf effects on Miz1 are mediated by
recruitment of Myc
To substantiate the assumption that Myc is required for Arf to inhibit Miz1 function,
we used three previously characterized Miz1 mutants which are impaired in binding to
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Myc [Peukert et al., 1997]. The Miz1 Δ33 deletion still retains some binding affinity to
the Myc-binding domain localized between the 12th and 13th zinc finger. In contrast
to that, the Miz1 Δ75 deletion and the quintuple point mutation Miz1 4Pro completely
abrogate Myc binding. All three mutants still bind to p14Arf (summarized in Figure 4.9
A). The solubility analysis showed that Miz1 mutants which cannot bind to Myc are
not sequestered into less soluble complexes upon overexpression of Arf (Fig. 4.9 B). This
directly correlates with any remaining binding ability of the Miz1 mutant to Myc, as Miz1
Δ33 becomes less soluble still. I also tested if the Miz1 mutants can still be repressed
by Arf in their ability to transactivate the P15INK4B reporter. The depiction as fold
repression shows that the Myc binding domain of Miz1 is also needed for Arf to repress
the Miz1 transactivation function (Fig. 4.9 C). In addition, immunofluorescence analysis
revealed that a Miz1 mutant devoid of Myc binding does not form intranuclear foci upon
Arf expression (Fig. 4.9 D). Finally, Miz1 Δ75 cannot be sumoylated anymore. Please
note that expression of NPM also inhibits the sumoylation, which adds up to the effects
presented in 4.1.4 on page 61.
In sum, the ability of Miz1 to bind to Myc is needed for the Arf-induced change in solubility,
repression of transactivation, foci formation and sumoylation of Miz1.
Figure 4.9. (facing page):
Miz1 mutants not binding to Myc fail to respond to Arf 1
A. Overview of Miz1 mutants, all of them being capable of binding to p14Arf [Herkert et al., 2010]. ZF =
zinc finger
B. The solubility assay was performed as in Figure 4.3.
C. The luciferase assay was performed as in Figure 4.5. Error bars represent standard deviation of biological
triplicates.
D. Immunofluorescence analysis was performed as in Figure 4.1.
E. His-Sumo2 pulldown was performed as described in 4.7 B. Note that for this assay Sumo1 instead of
Sumo2 was used, which is further analyzed in section 4.2.1.
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4.2. Sumoylation of Miz1
4.2.1. Miz1 can be modified by both main Sumo isoforms
There are three isoforms of Sumo expressed in higher eucaryotes. Sumo1 is 50% identical
in sequence to Sumo2/3, which form a distinct subfamily being very similar in sequence
and function [Hay, 2005]. Hence, I only considered the specific Sumo1 and Sumo2
isoforms for the sumoylation analysis. I performed in vivo sumoylation assays in HeLa
cells by expressing His-tagged Sumo1 or Sumo2 in addition to proteins involved in the
sumoylation, either as targets, inducers or inhibitors of this modification. Upon denaturing
lysis, sumoylated protein species were pulled down using Ni2+-NTA-agarose. Subsequent
Western Blot analysis showed the modification status of the protein of interest, a higher
migrating band after pulldown being indicative for a Sumo modification.
In vivo sumoylation assays with overexpression of Miz1, p14Arf and His-Sumo revealed
that Miz1 can be sumoylated by Sumo1 and Sumo2, and that this is strongly induced by
Arf (Fig. 4.10 A). Miz1 antibody staining of pulldown samples showed that also unmodified
Miz1 of a size of about 100 kDa sticks to the agarose beads used for this kind of experiment.
However, three to four higher migrating bands, the most prominent one at around 150 kDa,
could clearly be distinguished and are in part also visible in the input samples. To validate
that this size shift really signifies sumoylation, I performed an in vivo sumoylation assay
upon depletion of the E2 enzyme Ubc9 (Fig. 4.10 B). Expression of a set of four siRNAs
against Ubc9 completely abrogated any higher migrating bands of Miz1 in the pulldown
samples in contrast to expression of control siRNA.
4.2.2. Miz1 is sumoylated at lysine 251
Sumo proteins can be covalently attached to lysine residues in a target protein. The
majority of sumoylation sites follow the consensus motif Ψ-K-X-E/D, with Ψ being a bulky
hydrophobic amino acid [Bernier-Villamor et al., 2002]. To find the major sumoylation site
in Miz1, I applied the SUMOsp software tool for in silico sumoylation site prediction [Xue
et al., 2006]. The algorithm suggested five possible sumoylation sites in Miz1 (Fig. 4.11
A). To analyze if sumoylation occurred at one of these lysines, I generated five different
mutants of Miz1. In each mutant a single lysine was replaced with an arginine, mimicking
an unmodified lysine at the respective site (K{number}R). Additionally I created a Miz1
mutant combining all lysine to arginine replacements (KR5). I analyzed these mutants in
a His-Sumo2 pulldown which showed sumoylation of all single KR mutants except K251R,
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Figure 4.10.:
Miz1 can be sumoylated by Sumo1 and Sumo2 which is induced by Arf
A. HeLa cells were transfected with the indicated plasmids and harvested 24 h later under denaturing condi-
tions. His-Sumo modified proteins were pulled down using Ni2+-NTA-agarose and analyzed via Western
Blot using a 7.5% input sample.
B. HeLa cells were first transfected with a combination of four siRNAs directed against Ubc9 or a control
siRNA, 24 h later with the indicated protein expression plasmids. His-Sumo assays were performed as
described in A, protein depletion of Ubc9 was verified via Western Blot.
where the strong shifted band of about 150 kDa was no longer detectable (Fig. 4.11 B). The
KR5 mutant recapitulated the K251R phenotype without further decrease in sumoylation.
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Figure 4.11.:
Miz1 can be sumoylated at lysine 251
A. The diagram illustrates the lysines in Miz1 predicted to be sumoylated. The corresponding sumoylation
motifs are shown below. ZF = zinc finger
B. Five Miz1 mutants with single lysines replaced by arginines were generated (K{number}R). Additionally,
a mutant comprising all five replacements was used (K5R). In vivo sumoylation assays were performed
as described in Figure 4.10 A.
4.2.3. Validation of the sumoylation site in Miz1
To confirm the notion that the sumoylation machinery is recruited to the sumoylation
consensus motif around lysine 251, I generated two more Miz1 mutants. I replaced the
two other crucial amino acids of the same motif, valine 250 and glutamic acid 253 with
alanines. His-Sumo pulldown experiments showed that mutation of either of the three vital
amino acids in the consensus motif lead to a significant loss in sumoylation, with mutation
of valine 250 displaying the mildest effect (Fig. 4.12 A). Moreover, lysine 251 in Miz1 was
confirmed as the target amino acid for sumoylation not only by Sumo2 but by both the
Sumo1 and Sumo2 isoforms (Fig. 4.12 B).
4.2. Sumoylation of Miz1 73
Figure 4.12.:
Validation of the sumoylation site in Miz1
A. Two Miz1 point mutants with valine 250 or glutamic acid 253 replaced by alanine were generated (V250A,
E253A). In vivo sumoylation assays were performed as described in Figure 4.10 A.
B. In vivo sumoylation assays were performed as described in Figure 4.10 A, using both the Sumo1 and
Sumo2 isoforms.
4.2.4. Arf induces sumoylation of Miz1 by inhibiting Senp3
Arf can mediate the sumoylation of proteins through its ability to inhibit the Sumo-specific
protease Senp3 [Haindl et al., 2008]. To do so, Arf triggers sequential phosphorylation,
ubiquitination and subsequent proteasomal degradation of Senp3 [Kuo et al., 2008]. To
test if Senp3 might be involved in inhibiting sumoylation of Miz1, I performed His-Sumo
pulldowns while expressing Senp3 wild type and the catalytically inactive mutant Senp3
C352S in addition to Miz1 and p14Arf. Strikingly, overexpression of Senp3 inhibited the
sumoylation of Miz1, both with and without induction by p14Arf. In contrast, expression
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of the catalytically inactive mutant of Senp3 further promoted the sumoylation of Miz1.
The Senp3 C352S mutant most likely acts as a dominant-negative protein for the endoge-
nous Senp3 as has been shown before using another catalytically inactive mutant of this
enzyme [Gong and Yeh, 2006]. Thus, Arf induces the sumoylation of Miz1 by inhibiting
its desumoylation by the Sumo protease Senp3.
Figure 4.13.:
Arf induces sumoylation of Miz1 by inhibiting the Sumo protease Senp3
Senp3 wild type and the catalytically inactive mutant Senp3 C352S were expressed in addition to Miz1
and p14Arf. In vivo sumoylation assays were performed as described in Figure 4.10 A. Half the amount
of Arf was transfected compared to the previous experiments to possibly allow further upregulation in
the sumoylation extent of Miz1.
4.2.5. Miz1 sumoylation is not increased upon exposure to various stress stimuli
In all previous experiments, sumoylation was analyzed upon transfection of Sumo and its
target protein Miz1. To verify sumoylation on an endogenous level, I performed His-Sumo
pulldown experiments either without any kind of enforced expression or by infecting near
to endogenous amounts of Miz1. However, I could not verify sumoylation of endogenous
or virally infected Miz1 in pulldown experiments (data not shown). This might be due
to the short half-life and the usually very low steady-state level of the Sumo modifica-
tion [Johnson, 2004; Hay, 2005] which makes it hard to be detected on an endogenous level.
Overall sumoylation is increased upon exposure to various stresses such as heat shock,
osmotic or ethanol stress [Saitoh and Hinchey, 2000]. The response to oxidative
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Figure 4.14.:
Miz1 sumoylation is not increased upon treatment with various stress stimuli
In vivo sumoylation assays were performed as described in Figure 4.13, using a lower amount of p14Arf.
HeLa cells were treated with the indicated stress conditions before harvesting by scraping off cells from
the dish.
76 Chapter 4: Results
stress varies depending on the concentration of H2O2 [Bossis and Melchior, 2006]. A
concentration of 1mM H2O2 induces a Uba2-Ubc9 crosslink and rapid loss of over-
all sumoylation by Sumo1 and Sumo2. Higher H2O2 concentrations such as 100mM
again induce accumulation of Sumo conjugates by now also inhibiting the Sumo peptidases.
I performed in vivo sumoylation assays assays upon various kinds of stress treatments to
determine a condition which might be used to visualize endogenous sumoylation of Miz1.
I transfected HeLa cells with Miz1, p14Arf and either His-Sumo1 or His-Sumo2. The
stress treatment was either applied before scraping the cells off the dish (Fig. 4.14) or
after detaching the cells by trypsinisation and treating them in a reaction tube (obtaining
essentially the same results, data not shown). All stresses which had been shown to trigger
overall sumoylation did not visibly upregulate the extent of Miz1 sumoylation under these
conditions, but rather diminished it. Treatment with low concentrations of H2O2 (0.1mM)
reduced the sumoylation as expected. In sum, none of the stresses previously shown to
trigger overall sumoylation had an inducing effect on the sumoylation of Miz1.
4.2.6. Miz1 K251R cannot phenotypically be distinguished from Miz1 wild type in
inhibiting cell growth
Next I assessed if the K251R mutant of Miz1, which displayed a defective sumoylation in
the in vivo sumoylation assays, shows a different phenotype compared to Miz1 wild type
in growth behaviour. U2OS cells do not actively express p14Arf, as their INK4a/Arf locus
is silenced by DNA methylation [Badal et al., 2008]. I used these osteosarcoma cells for
the following experiments, infecting relatively low levels of Arf compared to the previous
transfection assays.
Miz1 has been shown to repress cell growth in colony formation assays due to expression
of CDK inhibitors [Staller et al., 2001]. I lentivirally infected U2OS cells with Miz1 wild
type and K251R in combination with p14Arf and monitored the cell growth in a growth
curve and by colony assay. Miz1 and p14Arf alone induced an inhibition of growth as
expected, the combination of the two revealed a more severe arrest phenotype. However, I
could not distinguish Miz1 wild type and the non-sumoylatable K251R mutant within this
experimental setup (Fig. 4.15). I obtained the same results using lentiviral infection in
the p14Arf expressing HeLa cells and retroviral infection of LS174 cells (data not shown).
It should be noted that the extent of the growth arrest induced by Miz1 is dependent
on serum conditions and varies from mild growth inhibition (as seen in Figure 4.15) to
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Figure 4.15.:
Miz1 wild type and K251R show the same growth arrest phenotype
A. U2OS cells were lentivirally infected with empty vector, Miz1 wild type or Miz1 K251R and selected
for expression of these proteins by a two-day puromycin treatment. Then either p14Arf or an empty
construct were infected and 25,000 cells seeded on 6 cm dishes. After 6 days cells were subjected to
crystal violet staining.
B. Expression of proteins was detected by Western Blot analysis two days after Arf infection.
C. Cell growth was monitored by seeding 100.000 U2OS cells onto 6cm dishes one day after Arf infection
and counting cells each of the five following days.
a complete block in proliferation (as shown by Staller et al. [2001]). This was discovered
through direct experimentation using twelve different kinds of sera (data not shown).
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4.2.7. Miz1 wild type and the non-sumoylatable mutant show the same
phenotype upon DNA damage
It is known that Miz1 plays a role in DNA damage, for example upon treatment of cells
with ultraviolet radiation (UV). Miz1 activates transcription of the p21cip1 gene upon
UV-B irradiation. Miz1 also releases a fraction of the topoisomerase II binding protein 1
(TopBP1) from the chromatin where it is kept in unstressed cells to be protected from
degradation by HectH9. TopBP1 activates the Atr master kinase in the DNA damage
response which leads to activation of downstream targets such as Chk1 and p53 [Herold
et al., 2008].
To determine if sumoylation of Miz1 may play a role in this process, I compared Miz1 wild
type and the non-sumoylatable mutant in their response to UV-B. I lentivirally infected
LS174T human colon adenocarcinoma cells also used in Herold et al. [2008] with an empty
vector control, Miz1 wild type and the K251R mutant. I treated cells with UV-B for 60
seconds, then harvested them for FACS analysis and Western Blot after 0, 1, 2, 4 or 6
hours. The Western Blot shows expression of the two Miz1 variants, as well as expression
of activated Chk1 (phosphorylated at Ser 345) which is indicative of active Atr signaling
(Fig. 4.16 A). In the empty vector situation, phospho-Chk1 levels increase shortly after
UV-B treatment, then rapidly decline again. Expression of both Miz1 wild type and the
K251R mutant induce a stronger increase of phospho-Chk1 which is retained active for a
longer time as has been observed before. The FACS analysis shows a decrease in G2/M
phase and a slight increase of the subG1 content for the empty vector infected cells over
time, reflecting a previously characterized G1 and S phase arrest with mild apoptosis upon
UV-B treatment (Fig. 4.16 B). Infection of Miz1 wild type and the K251R mutant again
shows a similar phenotype, both inducing a decrease of cells in G2/M phase as well as
a fairly strong apoptotic response at the later time points. All in all, I could not detect
major differences between overexpression of Miz1 wild type and the non-sumoylatable
mutant combined with UV-B treatment with this experimental setup.
4.2.8. Global gene expression pattern induced by Miz1 wild type and the
non-sumoylatable mutant
To assess if the global gene expression pattern that results from overexpression of Miz1 wild
type is different to the one induced by the Miz1 non-sumoylatable mutant, we performed
a genome-wide microarray analysis. I lentivirally infected U2OS cells with Miz1 wild
type and K251R in combination with an empty vector construct or p14Arf (Fig. 4.17 A).
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Figure 4.16.:
Miz1 wild type and K251R respond to UV-B irradiation in the same way
A,B. LS174T cells were lentivirally infected with empty vector, Miz1 wild type or Miz1 K251R and selected
for expression of these proteins by a two-day puromycin treatment. Cells on 10 cm dishes were treated
with a dose of 500 J/m2 UV-B all at the same time and then harvested 0, 1, 2, 4 or 6 hours later by
trypsination, including floating cells in the medium supernatant. Cells were split up, one half was boiled
in hot SDS sample buffer and subjected to Western Blot, using Vinculin as a loading control (A). The
other half was fixed in ethanol and subjected to PI-FACS (B).
I harvested the cells and isolated the RNA which was subjected to microarray analysis
performed by Michael Krause. Bioinformatician Lukas Rycak analyzed the raw data (both
from IMT Marburg).
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The Venn diagrams in Figure 4.17 B give a first impression of the number of regulated genes
and their distribution. All genes that are twofold up- or downregulated in comparison to
the empty vector situation were considered. The analysis reveals that expression of Arf
strongly enhances the ability of both Miz1 wild type and the K251R mutant to modulate
transcription, which is independent of the effects induced by Arf alone (as already observed
in Herkert et al. [2010]). Specifically, Miz1 wild type modulates 1886 genes more than
twofold in the presence of Arf, but only 1391 in its absence. Similarly, expression of Arf
enhanced the number of Miz1 K251R-modulated genes from 1622 to 2022. To see if Miz1
wild type and the non-sumoylatable mutant have different effects on either repression or
activation of genes, I generated Venn diagrams for either twofold up- or downregulation of
genes in the presence or absence of Arf (Fig. 4.17 C). The overlap between genes regulated
by Miz1 wild type and the K251R mutant is highly significant in each of the four Venn
diagrams. However, there are also several genes only regulated in either of the two Miz1
conditions. Most prominently, Miz1 K251R downregulates 765 genes in comparison to 516
genes downregulated by Miz1 wild type. Also, overexpression of Miz1 wild type together
with Arf leads to upregulation of 1088 genes while K251R together with Arf upregulates
1246 genes. Taken together, the expression patterns of Miz1 wild type and the non-
sumoylatable mutant are highly similar but also exhibit some differences.
Validation of the microarray
Gene Ontology (GO) term analysis using DAVID revealed no apparent groups of genes
that are differentially regulated when comparing Miz1 wild type with the K251R mutant
(data not shown). However, if assumed that infection of Miz1 wt + Arf but not Miz
K251R + Arf leads to sumoylation of Miz1, it should be possible to identify a set of genes
that is regulated differently comparing sumoylated and non-sumoylated Miz1. If this kind
Figure 4.17. (facing page):
Microarray results summarized in Venn diagrams
A. U2OS cells were infected with lentiviruses expressing the indicated proteins or with empty vector controls.
After selection, cells were harvested and a fraction of them analyzed via hot SDS lysis and Western Blot.
From the remaining cells the RNA was extracted and examined for quality and quantity, then used for a
microarray experiment.
B. Two Venn diagrams depicting the overlap in genes up- or downregulated twofold in comparison to the
empty vector condition are shown.
C. The overlap of genes that are either up- or downregulated are depicted in separate Venn diagrams for
the different infection conditions comparing Miz1 wild type and the non-sumoylatable K251R mutant.
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of sumoylation-based differential regulation would occur, a set of four regulation patterns
considering the six infection conditions could be imagined. A certain group of genes could
show up- or downregulation only when Miz1 is sumoylated (only Miz1+Arf up, only
Miz1+Arf down), another group of genes could be regulated only in absence of Miz1
sumoylation (all up except Miz1+Arf, all down except Miz1+Arf). I sorted the list of all
≥ twofold regulated genes from the microarray, each in comparison to the empty vector
condition, according to these four regulation patterns.
In Figure 4.18 A, these patterns become apparent: Each of the four panels represent a
list of genes picked out as described above. The bars represent an average of the logFC
values of all genes in the respective group. The all up except Miz1+Arf, all down except
Miz1+Arf groups count only comparably few genes (30 and 18 genes), which when
averaged do also not reflect strong differences among the distinct infection conditions.
In contrast to that, the only Miz1+Arf up, only Miz1+Arf down groups of genes are
considerably larger (211 and 341 genes) and the Miz1+Arf condition stands out more
clearly as being regulated in a different manner. Thus, I focused on these two groups of
genes for further analysis.
To validate the microarray, I analyzed several top regulated genes which showed a strong
up- or downregulation in one of the infection conditions by qRT PCR. All of these reflected
the same regulation in microarray and qRT PCR (data not shown). Next, I picked several
Figure 4.18. (facing page):
Grouping of genes and validation of the microarray data by qRT PCR
A. Genes were picked that show a differential regulation for the Miz1 + Arf condition, where Miz1 is possibly
sumoylated. Four groups of genes were generated that either showed a ≥ twofold regulation only in the
Miz1 + Arf condition (only Miz1+Arf up, only Miz1+Arf down) or in all conditions except Miz1 + Arf
(all up except Miz1+Arf, all down except Miz1+Arf). The number of genes in each list is specified
in the heading. The bars in each of the four panels represent the averaged logFC values of all genes in
the respective group which were analyzed for the different infection conditions. wt = Miz1 wild type,
K251R = Miz1 K251R
B. Six genes were picked out of the only Miz1+Arf down group and validated by qRT PCR with the same
RNA used for the microarray. The upper panel shows the microarray data for each gene compared to
the empty vector control, the reference point at zero is set as the average value of all analyzed samples
from the whole array. The lower panel shows the qRT PCR analysis with the same genes normalized to
beta-2-microglobulin. The relative mRNA levels were each set in reference to the value of the empty
vector infection which was arbitrarily set to 1.
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genes out of the aforementioned two groups of genes and also analyzed them by qRT
PCR, focusing on genes which show the most divergent regulation in the sumoylated Miz1
condition. In Figure 4.18 B the microarray data of the validation targets from the only
Miz1+Arf down group is shown together with the qPCR analysis. While the microarray
exhibits a twofold repression only in the Miz1+Arf condition for these genes, this cannot
be observed for the qRT PCR validation in the same manner. Even though repression
does occur, except for Wnt16, the ratio between the different conditions in the qPCR does
not reflect the microarray output. I also observed this for genes validated from the only
Miz1+Arf up group and in an independent experiment with RNA isolated from newly
infected cells (data not shown). With this analysis, I could not identify a group of genes
that are differentially regulated in the Miz1+ Arf condition.
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4.3. Sumoylation of Myc
4.3.1. C-Myc and N-Myc can be modified by both Sumo isoforms
In the previous chapter I could show that Arf-induced complex formation of Miz1, Arf
and Myc goes along with sumoylation of Miz1 at a specific lysine. To reveal if Sumo
modification of Myc is possible as well, I performed a sumoylation analysis using the two
best characterized Myc isoforms, the abundant c-Myc and the neuronal N-Myc. In vivo
sumoylation assays were performed in HeLa cells as described in 4.2.1 on page 70.
The pulldown experiments revealed that upon overexpression of c-Myc together with
His-Sumo2, a whole ladder of higher migrating Myc species can be pulled down (Fig. 4.19
A). Arf expression does not stimulate an increase of the sumoylation of Myc as it
does for Miz1 (data not shown). Unmodified c-Myc with a size of about 55 kDa sticks
to the agarose beads, which I had already observed for Miz1. N-Myc can also be
sumoylated by both the Sumo1 and Sumo2 isoforms, which is later shown for c-Myc as
well ( 4.3.6 on page 90). The major N-Myc sumoylation band at around 90 kDa can
already be detected in the input samples, the overall sumoylation pattern in the pulldown
samples is characterized by a ladder of higher migrating bands (Fig. 4.19 B). Substan-
tially less unmodified N-Myc sticks to the agarose beads used in the in vivo sumoylation
assays, thus I performed the first part of the sumoylation analysis using the N-Myc isoform.
I blotted the pulldown samples for N-Myc sumoylation in addition directly with Sumo1
and Sumo2 antibodies, showing a major increase in sumoylated proteins upon N-Myc
overexpression for both Sumo1 and Sumo2 (Fig. 4.19 C). The proteins detected in the Sumo
blots exhibit the same band pattern with and without transfection of N-Myc, including
a characteristic 90 kDa protein which likely is RanGap [Saitoh and Hinchey, 2000]. HeLa
cells do not endogenously express N-Myc, which leads to the conclusion that transfection
of N-Myc together with Sumo increases sumoylation of other targets.
4.3.2. Myc is subjected to multisumoylation
The His-Sumo pulldown with both c- and N-Myc does not show clearly distinguishable
higher migrating bands which are indicative for attachment of a single or a few Sumo
molecules. Instead, a first prominent band shifted up about 45 kDa is followed by a ladder
of bands reaching up to the 170 kDa range. To verify this as sumoylation and to explore the
nature of the modification, I first performed an in vivo sumoylation assay with and without
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Figure 4.19.:
c-Myc and N-Myc can get sumoylated by Sumo1 and Sumo2
A. Sumoylation of c-Myc by Sumo2. HeLa cells were transfected with the indicated plasmids and harvested
24 h later under denaturing conditions. His-Sumo modified proteins were pulled down using Ni2+-
NTA-agarose and analyzed via Western Blot with a 7.5% input sample. This procedure applies to all
sumoylation assays in the following Figures, any changes will be specified.
B. Sumoylation of N-Myc by Sumo1 and Sumo2 in the His-Sumo pulldown.
C. His-Sumo pulldown samples of the experiment in B were blotted for Sumo1 and Sumo2, respectively.
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depletion of the E2 enzyme Ubc9. Expression of an siRNA pool against Ubc9 severely
diminished higher migrating bands of pulled-down N-Myc throughout the whole size range
(Fig. 4.20 A). Next, I tested if the unusual pattern of many higher migrating bands results
from poly-Sumo chains or ubiquitination of a Sumo molecule that is attached to Myc. I
generated two mutants of Sumo2, which either lack the internal sumoylation site or all sites
that have been shown to be possible targets for ubiquitination [Tatham et al., 2008]. Both
Sumo2 mutants showed the same ability to modify N-Myc as wild type Sumo2 (Fig. 4.20
B). Therefore, polysumoylation as well as formation of mixed Sumo/ubiquitin chains can
be excluded as the reason for the distinctive size shift. This is further supported by the
fact that Sumo1 modification of Myc also shows a ladder of shifted bands, even though
Sumo1 lacks an internal sumoylation site which is necessary for poly-Sumo chain formation.
Sumoylation of Myc could result in subsequent ubiquitination at internal lysines in the
Myc sequence. To investigate if sumoylation promotes ubiquitination of Myc, I performed
a His-ubiquitin assay. To prevent degradation of ubiquitinated Myc I treated cells with
proteasome inhibitor before harvesting. Otherwise the same setup and protocol as used for
the His-Sumo pulldown was applied. Overexpression of an HA-tagged version of Sumo2
resulted in a visible band shift in the N-Myc input sample and an accumulation of sumoy-
lated species in the high kDa range on the HA-Sumo blot. Coexpression of N-Myc and
ubiquitin resulted in polyubiquitination of N-Myc as expected, but this did not increase
upon additional expression of Sumo2 (Fig. 4.20 C). Proteasome inhibition never resulted in
accumulation of sumoylated Myc using differently tagged constructs of Sumo1 and Sumo2
(data not shown).
4.3.3. Sumoylation consensus sites in Myc
Sumoylation often occurs within the defined consensus motif Ψ-K-X-E/D (see also 4.2.2 on
page 70). The SUMOsp software tool for in silico sumoylation site prediction proposed one
non-consensus sumoylation site in c-Myc which overlapped with one of the two predicted
consensus sites in N-Myc. To verify if these sites could be preferred targets for modification
by Sumo, I generated two N-Myc mutants. For the KR3 mutant I replaced two adjacent
lysines in addition to the predicted lysine 351 by arginines, the K413R mutant just contains
one replacement (Fig. 4.21 A). An in vivo sumoylation assay revealed that the KR3 and
K413R mutant can both be sumoylated like wild type N-Myc, even though the KR3 mutant
shows minor changes in the sumoylation pattern in the lower kDa range, which is also
reflected in the input (Fig. 4.21 B). Sumoylation consensus lysines in Myc are therefore
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not exclusive targets for sumoylation, as already expected from the notion that Myc must
be multisumoylated.
4.3.4. Determining a preferred region for sumoylation in Myc
To analyze if sumoylation of Myc plays a biological role, a mutant of Myc refractory to
sumoylation that could be compared to wild type Myc would be very useful. From the
previous experiments it coud be concluded that sumoylation must take place at multiple
lysines in the Myc sequence. I therefore investigated if these lysines could be reliably
determined to generate a non-sumoylatable Myc mutant.
C-Myc contains 25 lysines. Two mutants of c-Myc were provided by Laura A. Jänicke,
which only contain lysines in either the N-terminal or the C-terminal half, the remaining
lysine residues replaced by arginines. In vivo sumoylation assays with Sumo1 and Sumo2
revealed that both mutants were severely depleted for sumoylation, especially in the higher
kDa range. This was far more prominent for the mutant that lacks the lysines in the C-
terminus, which contains 18 out of the total 25 lysines (Fig. 4.22 A).
4.3.5. Using single lysine mutants of Myc to find target sites for sumoylation
Mutants of c-Myc containing either only C- or N-terminal lysine residues did not reveal a
preference for sumoylation considering the different numbers of lysines in either half of the
protein. To investigate the sumoylation sites in Myc more thoroughly, I used mutants of c-
Myc provided by Nikita Popov which either contain no lysines at all (K-less) or only single
lysines (Kx). All remaining lysine residues were replaced by arginines. I compared the
25 mutants each to wild type Myc and the non-sumoylatable K-less mutant as a negative
control for their potential to be sumoylated, several examples are shown in Figure 4.23 A
Figure 4.20. (facing page):
Myc is multisumoylated by Sumo1 and Sumo2
A. HeLa cells were first transfected with a pool of four siRNAs directed against Ubc9 or a control siRNA,
24 h later with the indicated protein expression plasmids. In vivo sumoylation assays were performed as
described in Figure 4.19 A, protein depletion of Ubc9 was verified via Western Blot.
B. In vivo sumoylation assays were performed using a Sumo2 mutant unable to form poly-Sumo chains
(K11R) or one that is refractory to chain-formation and internal ubiquitination (K 11, 33, 35, 42, 45 R).
C. The His-ubiquitin assay was performed following the same protocol as used for the His-Sumo pulldown.
Cells were treated with 10μM MG-132 for 6 hours before harvesting to prevent degradation of ubiquiti-
nated Myc in the proteasome.
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Figure 4.21.:
Sumoylation consensus sites in Myc are not exclusive targets for sumoylation
A. Possible sumoylation sites in N-Myc and c-Myc are listed. The diagram illustrates the lysines replaced
by arginines for the KR3 (K 348, 349, 351 R) and the K413R mutant in relation to important functional
motifs in the Myc protein. Lysine 323 in c-Myc aligns with lysine 348 in N-Myc. MB = Myc box, BR
= basic region, HLH = helix-loop-helix, LZ = leucine zipper
B. In vivo sumoylation assays were performed using the N-Myc KR3 and K413R mutants described in A.
and B. The extent of sumoylation was quantified for each mutant and plotted in Figure 4.23
C. The analysis revealed a cluster of preferred sumoylation sites between lysine 289 and
355. This region overlaps with the sumoylation consensus site in N-Myc around lysine 351.
4.3.6. Central target lysines play an important role in the sumoylation of c-Myc
To verify if the central sumoylation cluster in c-Myc is decisive for sumoylation of the full-
length protein, I generated two additional mutants. One had six lysines from the cluster
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Figure 4.22.:
Myc mutants lacking C- or N-terminal lysines in the sumoylation assay
A. The diagram depicts the localization of all 25 lysines in c-Myc. Brackets indicate which lysines were
mutated to arginines in the C- or N-terminal half of c-Myc.
B. In vivo sumoylation assays were performed using c-Myc mutants containing only N-terminal lysines (K-
less K-Nter) or only C-terminal lysines (K-less K-Cter) respectively. Note that these and the following
lysine mutants of c-Myc all contain an N-terminal HA-tag.
mutated to arginines (KR6), the other one exclusively contained seven lysines from the
same region (K-less R7K). The KR6 mutant could still be sumoylatated to a significant
extent in comparison to wild type c-Myc and the lysine-less mutant (Fig. 4.24 A). The
mutant with the reconstituted lysines showed some sumoylation, but the extent of the
modification did not reach the same level as for wild type c-Myc (Fig. 4.24 B). It can
thus be concluded that the previously identified cluster for c-Myc modification by Sumo is
important for the sumoylation of c-Myc without being the sole Sumo target region.
92 Chapter 4: Results
4.3.7. Myc sumoylation is not increased upon exposure to various stress stimuli
I could not detect sumoylation of Myc without overexpression of the protein when
performing His-Sumo pulldowns. Increasing the sumoylation of Myc might enable
visualization of an endogenous Sumo modification. Therefore, I applied different kinds of
stress treatments which are known to induce overall sumoylation to cells before harvesting
them for the pulldown experiments (see also 4.2.5 on page 74).
None of the stresses which had been shown to trigger overall sumoylation visibly induced
the extent of Myc sumoylation. Treatment with high concentrations of H2O2 (100mM)
abrogated the sumoylation of c-Myc completely and increased its nonspecific binding to the
agarose beads used for the pulldown (Fig. 4.24 A). Lower concentrations of H2O2 neither
induced nor diminished Sumo modification of Myc to a distinguishable extent (Fig. 4.24
B).
4.3.8. Myc contains the sequence of a possible Sumo interacting motif
The MYC family of oncogenes is evolutionary well conserved from insects to vertebrates,
although sequence conservation is limited to a few short domains [Schwinkendorf and Gal-
lant, 2009]. The most conserved domains are Myc box II and III, but there is an almost
equally conserved sequence in the central part of Myc. This has been first described as a
PEST sequence (amino acids 226 to 270 of murine c-Myc) which is necessary for ubiquitin-
mediated degradation but not as a region of direct ubiquitin attachment [Gregory and
Hann, 2000].
Interestingly, this highly conserved region fulfills all criteria for being a reverse Sumo
interacting motif (SIMr). SIMs interact with Sumo non-covalently and thus often mediate
the effects of sumoylation [Wimmer et al., 2012]. The sequence in the human c-Myc and
Figure 4.23. (facing page):
Single c-Myc lysine mutants reveal a cluster of preferred sumoylation sites
A.-B. In vivo sumoylation assays were performed using c-Myc mutants containing only single lysines (K-less
Kx), shown here are examples for ten mutants. The extent of sumoylation was compared by quantifying
higher migrating bands in relation to c-Myc sticking to the agarose beads in the pulldown samples, as
this proved to be more accurate than comparing with the input values.
C. The extent of sumoylation of each K-less Kx mutant was set in relation to the sumoylation of wild type
Myc, which was arbitrarily set to 1. Sumoylation clusters in a central domain of Myc at lysines 289, 298,
326 and 355.
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Figure 4.24.:
A cluster of lysines in the central region of c-Myc is an important target region for sumoylation
A. In vivo sumoylation assays were performed using a c-Myc mutant lacking six lysines from the sumoylation
cluster (KR6 = K 289,298,323,326,341,355 R) and [B.] one that only contained lysines in the cluster
region (K-less R7K = R 289,298,317,323,326,341,355 K).
N-Myc homologues and in orthologues from other species contains a core sequence of
three hydrophobic amino acids (IDVV) which complies with the SIM consensus sequence
V/I-X-V/I-V/I. This core is either followed by either a serine or a threonine and preceded
by an acidic stretch of aspartic and glutamic acids (Fig. 4.26 A).
Sumo interacting motifs often provide an interaction platform for sumoylated target and
effector proteins. As Myc is sumoylated at many different non-consensus sites, the internal
Figure 4.25. (facing page):
Sumoylation of c-Myc is not upregulated upon treatment with various stress stimuli
A.-B. HeLa cells were treated with the indicated stress conditions before harvesting by scraping off cells from
the dish and subjecting them to the usual His-Sumo pulldown procedure.
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Figure 4.26.:
Myc contains a highly conserved sequence which could be a Sumo interacting motif but which is not
needed for internal sumoylation of Myc
A. Sequence alignment between human Myc homologues and paralogues from different species reveals a
highly conserved sequence which fulfills all criteria for a reverse Sumo interacting motif (graph created
with CLC sequence viewer 6).
B.-C. In vivo sumoylation assays with a c-Myc ΔSIM deletion mutant lacking amino acids 249-272 and a Myc
ADAA point mutant with the hydrophobic isoleucine and the two valines replaced by alanines.
SIM could recruit a Sumo-loaded Ubc9 to the protein to enable sumoylation of Myc. This
has been shown for the ubiquitin ligase USP25 [Mohideen and Lima, 2008]. To test this,
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I generated two mutants of c-Myc, a deletion mutant lacking the whole conserved SIM
sequence area (Myc ΔSIM: Δ249-272) and a point mutant with the core hydrophobic
amino acids replaced by alanines (Myc ADAA). In vivo sumoylation assays revealed that
both mutants can be sumoylated to the same extent as wild type c-Myc (Fig. 4.26 B-C).
Thus, sumoylation of Myc is independent of its possible SIM sequence.
4.3.9. Non-covalent Sumo binding to Myc in vitro
To verify if the Sumo interacting motif is a veritable domain for non-covalent binding
of Myc to Sumo proteins, I performed in vitro binding assays. GST-tagged Sumo1, 2
and 3 isoforms were recombinantly expressed, then affinity purified with glutathione
sepharose beads. N-Myc, c-Myc and its ADAA mutant and two control proteins RNF4
and Ubc9 were generated by in vitro translation. The recombinant Sumo proteins bound
to sepharose beads were incubated with the in vitro translated proteins, the beads were
washed and the precipitates analyzed by Western Blot.
The binding analysis shows a clear but weak binding of c-Myc and N-Myc to the Sumo1
isoform, but not to Sumo2 or 3. This is however independent of the conserved domain in
Myc which was hypothesized to be a Sumo interacting motif (Fig. 4.26 B-C). RNF4 and
Ubc9 which contain validated Sumo interacting motifs both bind preferably to Sumo2 and
Sumo3 as expected and thus prove the assay to be functional (Fig. 4.26 D-E).
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Figure 4.27.:
Non-covalent binding of c-Myc and N-Myc to Sumo in an in vitro binding assay
A. GST-tagged Sumo1, 2 and 3 was expressed recombinantly in bacteria and affinity purified using glu-
tathione sepharose beads. Quantification by SDS-PAGE followed by coomassie staining verified equal
amounts of the different Sumo isoforms used for the following binding assay, GST served as an internal
control.
B.-E. Equal amounts of in vitro translated N-Myc, c-Myc wild type, c-Myc ADAA, HA-tagged RNF4 and Ubc9
were incubated with either GST alone or the different GST-Sumo isoforms bound to sepharose beads.
The precipitates on the beads were washed gently and visualized via Western Blot, comparing it to a
1% input of each in vitro translated sample.
Chapter 5.
Discussion
5.1. Arf inhibits Miz1 function by inducing a repressive Myc/Miz1
complex
The first objective of this thesis was to study a possible interaction between the three
proteins Arf, Myc and Miz1. The tumor suppressor p14Arf (p19Arf in mice) is encoded
by the INK4A/ARF locus and shares exon 2 with p16(Ink4a) in an alternate reading
frame, which gave Arf its name [Quelle et al., 1995]. While p16(Ink4a) inhibits cyclin D-
dependent kinases and thus regulates the retinoblastoma (Rb) protein to block G1-S
transition, Arf stabilizes p53 by inhibiting the ubiquitin ligase Mdm2 [Lin and Lowe, 2001].
Consequently, the two transcripts play a major role in protecting cells from oncogenic
transformation, which is underlined by the fact that the INK4A/ARF locus is frequently
deleted, mutated or epigenetically silenced in a wide array of human tumors [Lowe and
Sherr, 2003]. Arf can be activated by oncogenic signals such as elevated Myc activity,
which is counteracted by p53-dependent apoptosis [Zindy et al., 2003]. However, Arf has
been shown also to possess tumor suppressive p53-independent functions. This becomes
apparent in the higher tumor incidence of triple knockout mice lacking Arf, Mdm2 and
p53 in comparison to double knockout animals merely lacking p53 and Mdm2 [Weber
et al., 2000]. In reaction to oncogenic Myc for example, Arf does not only activate p53
but directly binds to Myc to inhibit its transactivation function on genes that activate
hyperproliferation and transformation [Qi et al., 2004].
The Arf protein has an unusual amino acid composition with more than 20% arginine
residues making it highly basic. Arf is unstructured and highly unstable unless bound
to other proteins, primarily to nucleophosmin (NPM) in the nucleolus [Sherr, 2006].
NPM acts as a molecular chaperone to form stable high-molecular mass complexes with
Arf. Nucleophosmin itself is also affected in its function as a endoribonuclease by this
interaction. It normally induces 28S rRNA maturation but this is inhibited by Arf which
promotes ubiquitination and degradation of NPM [Itahana et al., 2003]. Additionally,
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Arf stimulates sumoylation of NPM which again blocks its function in rRNA processing
[Haindl et al., 2008; Kuo et al., 2008].
5.1.1. Miz1 interacts with Arf and relocalizes it from the nucleoli into the
nucleoplasm
It has been established that Arf directly interacts with Myc in response to oncogenic
stress, and it is also known that Myc binds to Miz1 to repress transcription. It does so for
example by displacing an important coactivator of Miz1, nucleophosmin, which again is a
major interactor of Arf in the nucleolus. It was thus investigated, whether Arf and Miz1
could interact as well and if they influence each others localization.
The immunofluorescence analysis clearly showed that overexpressed Miz1 recruits endoge-
nous and exogenous Arf out of the nucleoli into the nucleoplasm (Fig. 4.1 on page 60). It
has been described that Arf is highly unstable and rapidly degraded in the proteasome
upon ubiquitination by the E3 ligase ULF, unless stabilized by nucleophosmin in the
nucleoli [Chen et al., 2010]. Even though it is generally accepted that nucleolar localization
may be a means of stabilizing and storing Arf, forms of Arf that do not accumulate in the
nucleolus retain the capacity to stabilize MDM2 [Llanos et al., 2001]. Other publications
even postulate that Arf primarily functions outside the nucleolus, and that sequestering
by NPM holds it inactive. This is supported by the fact that NPM and Mdm2 both bind
to the same N-terminal domain of Arf, probably in a competitive manner [Korgaonkar
et al., 2005]. Thus, it can be assumed that the recruitment of Arf out of the nucleoli
by Miz1 does not lead to degradation of Arf, as implicated by its strong nucleoplasmic
detection of both the endogenous and exogenous protein in the immunofluorescence.
While Arf is recruited out of the nucleoli into the nucleoplasm, the normally homogenous
distribution of Miz1 is also altered upon overexpression of Miz1 and Arf. In about 80% of
transfected cells, Miz1 is sequestered into subnuclear, foci-like structures. These partially
overlap with the Arf distribution indicated by a Pearson's coefficient of about 0.5. Miz1
has already been shown to be sequestered upon overexpression of Myc [Peukert et al.,
1997], but the resulting structures appear as larger pools of aggregated protein and do
not resemble the Arf-induced structures in direct comparison (not shown). I furthermore
tested if the Arf-induced Miz1 foci represent paraspeckles, several components of which can
bind to the Miz1-interacting protein TopBP1 [Kuhnert et al., 2012], or if they were PML
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bodies which show a similar phenotype to the Miz1 foci. Immunofluorescence analysis
upon overexpression of GFP-tagged proteins, PSF or P54nrb as protein components
of the paraspeckles or SP100 as part of the PML bodies, did not reveal a substantial
colocalisation of any of these in the Arf-induced Miz1 structures (data not shown).
Immunoprecipitation assays described in detail in Herkert et al. [2010] confirmed an in-
teraction between Miz1 and both human and mouse Arf. This interaction is independent
of nucleophosmin, which could act as a bridging protein between Miz1 and Arf, as the
reciprocal binding was also detected in NPM-/-/p53-/- MEFs. Quite the contrary, reconsti-
tution of NPM in these cells antagonized binding between Arf and Miz1, which I further
analyzed in Figure 4.4 on page 63. It should be noted, that Miz1 attachment to Arf could
be mediated by Myc, which is known to bind to Arf and Miz1 and according to recent
reports also to nucleophosmin [Li et al., 2008]. Indeed Myc plays an important role in
mediating the Arf effects on Miz1 as will be discussed below (see 5.1.5).
5.1.2. Arf reduces the solubility of Miz1 and inhibits its transactivation function,
which is counteracted by nucleophosmin
Arf expression markedly reduced the solubility of Miz1 (Fig. 4.3 on page 62). Such a
reduced extractability often goes along with formation of repressive histone modifications
such as trimethylated histone H3K9 [Kouzarides, 2007]. Chromatin immunoprecipitation
experiments indeed showed a strongly increased signal for H3K9triMe around the Miz1
binding site of the P15INK4B promoter upon Arf expression without affecting the Miz1
binding itself [Herkert et al., 2010].
To test wether Arf affects Miz1 function as a transcription factor, I performed luciferase
reporter assays using a P15INK4B promoter plasmid (Fig. 4.5 on page 64). Arf clearly
inhibited the Miz1-dependent transactivation, I obtained the same result using a P21CIP1
construct (data not shown). Nucleophosmin has been shown to act in the opposite
direction, it is an essential coactivator of Miz [Wanzel et al., 2008]. As NPM and Arf
bind to Miz1 in a competitive manner, it was not surprising to find that overexpression
of NPM abrogated formation of subnuclear Miz1 foci upon Arf expression. Likewise the
reduced extractability could also not be observed when NPM was expressed.
Expression of Arf also repressed Miz1 function in vivo. We expressed combinations of
Miz1 and p19Arf in Arf -/-, p53-/-, Mdm2-/- MEFs by retroviral infection. Flow cytometric
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analysis revealed that expression of Miz1 led to a G1 arrest, triggered by elevated amounts
of the cell cycle inhibitor p21Cip1, a direct Miz1 target [Wanzel et al., 2008]. Coexpression
of p19Arf abolished the G1 arrest and led to a transcription-independent S phase arrest
via Miz1 [Herold et al., 2002].
In sum, Arf represses Miz1 transactivation function which is accompanied by reduced
solubility of Miz1 and which may be accounted for by formation of heterochromatin on
its target promoters. The biological relevance of this repressive mechanism could be
verified in vivo by expressing Miz1 and Arf in p53-/-/Mdm2-/-/Arf-/- MEFs. Arf notably
diminished the Miz1-induced G1 arrest which normally follows upregulated p21 levels
upon overexpression of Miz1.
5.1.3. Arf induces anoikis via Miz1 target genes
A genome-wide gene expression study in U2OS cells showed a strong increase in the
number of repressed genes upon Miz1 and Arf overexpression [Herkert et al., 2010]. These
repressed genes comprise a subgroup of factors involved in cell adhesion, such as several
different integrins, which mediate contact between cells and the surrounding extracellular
matrix [Hynes, 2002]. Interestingly, many of these cell adhesion genes presented a
H3K9triMe signature close to the Miz1 binding sites on their promoters. As many epithelial
cells are dependent upon proper contact to the extracellular matrix, repression of this set
of genes leads to loss of cell adhesion and subsequently to a type of apoptosis called anoikis
[Reginato et al., 2003]. Indeed, retroviral overexpression of Miz1 and Arf in U2OS cells
which were additionally stressed by the selection process with two different antibiotics died
shortly after selection. To verify that detachment of cells is the cause and not the result
of apoptosis, we expressed the anti-apoptotic protein Bcl2 in these cells, which reduced
apoptosis measured by PI-FACS but did not impair the loss of cell adhesion [Herkert, 2010].
5.1.4. Arf induces sumoylation of Miz1 independently of other Arf-induced Miz1
phenotypes
It was proposed that one of the p53-independent functions of Arf is its ability to induce
sumoylation of proteins to which it binds, such as Mdm2 [Xirodimas et al., 2002],
p53 [Chen and Chen, 2003], Werners helicase [Woods et al., 2004] and notably also
nucleophosmin [Xirodimas and Lane, 2008]. The effects of sumoylation on Mdm2 and
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p53 are largely unknown, the Werners helicase is relocalized from the nucleolus to the
nucleoplasm upon sumoylation by Arf. Nucleophosmin is inhibited by sumoylation in its
function in rRNA processing, the detailed mechanism of this inhibition will be discussed
in 5.2.2. Sumoylation of transcription factors in most cases leads to transcriptional
repression, often through establishment of heterochromatic DNA complexes such as of
a H3K9triMe and H4K20triMe signature around binding sites of sumoylated Sp3. I thus
examined if Arf also induces sumoylation of Miz1.
I used His-Sumo pulldowns to extract all sumoylated proteins and subsequently detect
a protein of interest out of this pool with a specific antibody. The analysis revealed
that Miz1 is sumoylated by Sumo2, which is substantially increased by expression of
Arf (Fig. 4.6 on page 65). Details about the nature of the sumoylation of Miz1 will be
discussed in 5.2. The sumoylation-promoting effect of Arf is specific, as it does not induce
sumoylation of Myc (data not shown).
Further immunofluorescence experiments showed that exogenous Miz1 colocalized with
Sumo2 in the Arf-induced Miz1 foci to an exceptional degree, with a Pearsons's correlation
coefficient of about 0.9 (Fig. 4.6 on page 65). To validate if sumoylation is the cause and not
the result of foci formation, I depleted the Sumo E2 ligase Ubc9 via siRNA, which effectively
disrupts the sumoylation machinery [Lin et al., 2003]. The immunofluorescence analysis
showed that depletion of Ubc9 completely abrogated detection of any Sumo signal, which
might be due to its relative instability when not attached to a target protein. However, the
relocalization of Miz1 into subnuclear foci by Arf was unchanged. Additionally, depletion
of Ubc9 did not affect sequestration of Miz1 into insoluble complexes [Herkert, 2010].
A complete Ubc9 knockout in mice is embryonic lethal, but animals with just one allele
are unaffected [Nacerddine et al., 2005]. Indeed, cells only need 20% of physiological
Ubc9 levels to survive [Melchior, 2010a]. Thus an inefficient knockdown of Ubc9 in the
aforementioned experiments could prevent detection of the role of sumoylation in Miz1
sequestration into insoluble nuclear foci. This however seems unlikely regarding the major
effect of an Ubc9 knockdown on sumoylation of Miz1 in the His-Sumo pulldowns as seen
in Figure 4.10 on page 71.
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5.1.5. The effects of Arf on Miz1 require formation of a trimeric complex with
Myc
There are various reports describing a connection between Myc and Arf as well as Myc
and Miz1, which will be shortly reviewed below. Myc mediates repression of Miz1 just like
Arf does, thus it is possible that these three proteins act together in one complex which
was tested through direct experimentation.
Oncogenic stress such as elevated Myc activity induces expression and enhanced stability
of Arf. Precisely, Myc activates Arf transcription via FoxO [Bouchard et al., 2007] and
inhibits the ubiquitin E3 ligase Ulf which mediates degradation of Arf [Chen et al.,
2010]. Arf in turn represses Myc transactivation on genes that activate hyperproliferation
and transformation by directly binding to it, while it does not affect Myc-mediated
repression [Qi et al., 2004; Datta et al., 2004]. Furthermmore, Myc competes with NPM
for binding to Miz1 just like Arf (see also 5.1.1), and this effectively blocks transactivation
by Miz1 [Wanzel et al., 2008]. Miz1 is a main mediator of Myc-induced repression, and
overexpression of both proteins leads to subnuclear sequestration and reduced solubility
of Miz1 [Peukert et al., 1997], similarly to what was observed in this work.
Based on this knowledge, I examined if Arf induces formation of a repressive Arf/My-
c/Miz1 complex. N-terminal mutants of Arf revealed that it interacts with Myc and Miz1
through different domains. Myc interacts with the highly conserved N-terminal part of
the Arf protein (as shown before by Datta et al. [2004]), which is the same domain that
also binds to NPM [Bertwistle et al., 2004] and Mdm2 [Zhang et al., 1998]. In contrast,
Miz1 can still interact with an N-terminal deletion mutant of Arf (Fig. 4.7 on page 66).
Even though the interaction with Miz1 is not impaired, this Arf mutant is no longer
able to repress transactivation, induce sequestration into insoluble complexes or promote
sumoylation of Miz1. All these effects obviously require the presence of the N-terminal
domain of Arf.
To check if Myc colocalizes in the Arf-induced Miz1 foci, I performed an immunofluores-
cence analysis with overexpression of Miz1, Arf and c-Myc. Myc also recruits Arf out
of the nucleoli into the nucleoplasm as has been observed before [Datta et al., 2004] but
which is still under debate in the literature [Amente et al., 2006]. Upon overexpression
of Miz1, Myc evidently colocalizes in the subnuclear structures induced by Arf, with a
Pearson's correlation coefficient of about 0.85. This is highly dependent on the interaction
5.1. Arf inhibits Miz1 function by inducing a repressive Myc/Miz1 complex 105
of Myc with Miz1. A mutant of Myc that cannot bind to Miz1 (c-Myc V394D) does not
colocalize in a comparable manner with a Pearson's correlation coefficient of only 0.36.
In sum, Arf induces a highly significant colocalization of Miz1 with Myc in subnuclear
foci, Arf itself is part of these foci but to a slightly lesser extent (Pearson's correlation
coefficient of about 0.52, Fig. 4.1 on page 60). This could lead to the assumption that the
primary role of Arf is to induce the Myc/Miz1 repressive complex.
To further substantiate the notion that complex formation between Miz1 and Myc is
necessary for the effects of Arf on Miz1, we analyzed several mutants of Miz1 that are
impaired in Myc binding. These mutants of Miz1 were largely refractory to sequestration
into insoluble subnuclear complexes, failed to be repressed in reporter assays and could
also not be sumoylated in response to Arf expression. This is underlined by the fact that
only the Miz1 Δ33 mutant, which showed residual Myc binding activity, reacted to some
extent like wild type Miz1.
The importance of Myc in these mechanisms was furthermore supported by the observation,
that not only coexpression of Miz1 and Arf but also of c-Myc and Arf induced the anoikis
phenotype described in 5.1.3 on page 102. This is dependent on the interaction with Miz1,
as c-Myc V394D does not have the same phenotype [Herkert et al., 2010].
5.1.6. Relevance and interpretation of Myc as part of an Arf-induced repressive
complex on Miz1
Myc has been shown before to repress cell adhesion via Miz1, namely in hematopoietic
and epithelial cells [Frye et al., 2003; Gebhardt et al., 2006; Wilson et al., 2004]. This
mechanism is vital for example for keratinocyte stem cells to exit from their niche
and differentiate. Decrease in keratinocyte adhesion is dependent on formation of the
Myc/Miz1 complex, as Myc V394D fails to do so.
Additionally, the repressive Myc/Miz1 complex is already known to participate in
induction of apoptosis. Transcriptional repression of the anti-apoptotic Bcl2 and the cell
cycle inhibitor p21Cip1, which are normally induced by Miz1, is an essential step towards
Myc-induced apoptosis [Patel and McMahon, 2006; Seoane et al., 2002].
Miz1 and Arf can both inhibit cell cycle progression. Miz1 does so by activating transcrip-
tion of p15ink4b, p21Cip1 and p57Kip2 [Seoane et al., 2001, 2002; Adhikary et al., 2003],
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Arf can induce stabilization of p53 which also activates p21Cip1 [El-Deiry et al., 1993].
Still, the two interaction partners do not cooperate in inducing cell cycle arrest but rather
collectively inhibit cell adhesion which leads to apoptosis. Myc is the critical factor that
mediates this outcome.
The discovered mechanism may provide one answer to the question why oncogenic stress
induced by Ras or c-Myc has such different outcomes. Despite the fact that both oncogenes
activate the Arf/p53 signaling pathway, Ras induces senescence and c-Myc apoptosis. Even
though Arf inhibits Myc transactivation in a negative feedback loop, Myc's repressive
function remains unaffected so that a Myc/Miz1 complex can repress cell adhesion genes
and induce apoptosis.
5.1.7. Summary and model
Arf induces formation of a repressive Myc/Miz1 complex in characteristic subnuclear
structures, which exhibit a decreased solubility. In an independent next step, Arf induces
sumoylation of Miz1, which might be the cause for the observed heterochromatinisation
on the promoters around Miz1 binding sites. Participation of Myc is necessary and
decisive in all these steps. Effectively, a set of Miz1 target genes involved in cell adhesion
is repressed which finally leads to cell death via anoikis.
In a cellular context, these findings propose the following model (Fig. 5.1): In unstressed
cells, Arf is retained in the nucleolus by the abundant nucleophosmin, the latter can
also shuttle to the cytoplasm to act as a coactivator of Miz1. Oncogenic levels of Myc
induce relocalization of Arf into the nucleoplasm, where Arf and Myc outcompete NPM
for binding to Miz1 and induce a repressive Arf/Myc/Miz1 complex. Additionally, Arf
induces sumoylation of Miz1 which could lead to the recruitment of corepressors such as
histone methyltransferases which induce formation of heterochromatin on the promoters
of cell adhesion genes. The resulting loss of contact to the extracellular matrix finally
leads to anoikis.
In this model the formation of an Arf/Myc/Miz1 complex can be assigned with a tumor
suppressor function, as it leads to death of cells with increased Myc activity. But what
happens when apoptosis as the final outcome of the loss of cell adhesion is impaired?
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Figure 5.1.:
Model of Arf-mediated repression via a Myc/Miz1 complex
See text for explanation. Me3 = H3K9
triMe
There are several reports in the literature describing that breakdown of anoikis contributes
prominently to the malignancy of mammary and colon cancers [Yawata et al., 1998;
Streuli and Gilmore, 1999; Shanmugathasan and Jothy, 2000]. The exact mechanism how
cell death via anoikis is executed proves to be quite complex [Frisch and Screaton, 2001].
Integrin signaling molecules such as the focal adhesion kinase (FAK) or the integrin-linked
kinase (ILK) activate the PI3K survival pathway directly by activating Akt but also
through indirect mechanisms [Giancotti and Ruoslahti, 1999; Dedhar, 2000]. Inadequate
expression of integrins abrogates this pro-survival signaling. Another mechanism depends
on apoptosis regulators that serve as sensors for cytoskeletal integrity which is closely
linked to cell adhesion. Bim for example is normally sequestered by microtubule-associated
dynein light chain 1 (DLC1), when released (for example after taxol treatment). Bim
interacts with Bcl2 to inhibit it, which stimulates release of cytochrome C from the
mitochondria [Puthalakath et al., 1999; Strasser et al., 2000]. Bmf is sequestered by
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actin/myosin-associated dynein light chain-2 (DLC-2), and transferring cells from the
attached state into suspension allows for Bmf to complex and neutralize Bcl2 [Puthalakath
et al., 2001]. Both activation of Bim [Egle et al., 2004] as well as repression of Bcl2
[Eischen et al., 2001a] have also been reported to be fundamental steps on the way to
Myc-induced apoptosis.
If cell death upon loss of cell adhesion is impaired by failure of one of the mechanisms
described above, formation of the Arf/Myc/Miz1 complex could indeed support tumori-
genesis instead of inhibiting it. Cells would detach but stay alive, which may promote
invasiveness and metastasis. Anoikis resistance has been documented to enable cells
to survive after detachment from their primary site while travelling through the lym-
phatic and circulatory systems, thereby significantly increasing their malignant potential
[Simpson et al., 2008; Voulgari and Pintzas, 2009]. Myc has already been shown to play
an important role in regulating invasiveness and metastasis, for example by promoting
epithelial-mesenchymal transition [Wolfer and Ramaswamy, 2011]. One source reveals
that transcriptional repression of integrin α1 by N-Myc promotes invasiveness of human
neuroblastoma cells [Tanaka and Fukuzawa, 2008]. Another recent report describes that
Myc cooperates with Skp2 to recruit Miz1 and p300 into a transcriptional complex that
activates RhoA, which is necessary for migration, invasion, and lung metastasis in vivo
[Chan et al., 2010]. This was substantiated by the analysis of human prostate carcinomas,
which showed a significant correlation between expression of RhoA, Myc, Skp2 and Miz1
and metastasis.
All in all, formation of a repressive Arf/Myc/Miz1 complex may be the tumorsuppressive
response to elevated Myc levels, but could lead to promotion of metastasis if the apoptotic
outcome is impaired.
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5.2. Miz1 can be sumoylated at a specific lysine which is induced
by Arf
In the course of the experiments leading to the identification of a repressive Arf/Myc/Miz1
complex we also discovered that Arf can induce sumoylation of Miz1 by Sumo2. To learn
more about this so far unknown modification of Miz1, I analyzed which Sumo isoforms
bind to Miz1 at which site and tried to elucidate the exact function of this modification.
5.2.1. Arf induces sumoylation of Miz1 at lysine 251
I used in vivo sumoylation assays to pull down sumoylated proteins from a cell lysate
and subsequently compare the protein input with the sumoylated fraction. Concomitant
expression of Miz1, Arf and Sumo1 or Sumo2 showed several higher migrating bands in
the Western Blot analysis of Miz1 protein. These ranged from a shift in size of about
30 kDa to the most prominent band moving up about 50 kDa to a weaker band with a
70 kDa shift (Fig. 4.10 on page 71). The theoretical molecular weight of the Sumo proteins
is 11 kDa, however the size increase for each Sumo added is typically in the range of
15-17 kDa [Hilgarth and Sarge, 2005]. In all experiments Sumo1 which cannot form chains
sumoylated Miz1 with the same modification pattern as Sumo2. Thus, chain formation
cannot explain the unexpectedly big size shifts. Furthermore, depletion of Ubc9, the only
E2 ligase in the sumoylation process, completely abrogated all higher migrating bands
(Fig. 4.10 on page 71), which proves that these are not simply generated by independent
other kinds of modifications such as ubiquitination or acetylation. It is however possible,
that sumoylation attracts and is necessary for subsequent modifications of the Miz1
protein in form of other posttranslational modifications. Still, sumoylation alone could
induce this uncommonly big shift, which has been observed similarly for several other
proteins [Melchior, 2010b].
Finding sumoylation sites in target proteins is relatively straightforward. Most proteins
are sumoylated within the defined tetrapeptide Sumo consensus motif Ψ-K-X-E/D. The
Miz1 amino acid sequence contains four lysines surrounded by this motif (Fig. 4.11 on
page 72). A fifth one was predicted to possibly be sumoylated using an algorithm which
considers all known sumoylation sites. Point mutants that contained a charge-conserving
arginine instead of the lysine revealed that Miz1 can get sumoylated at lysine 251.
Technically, replacement of this lysine did not completely abrogate all higher migrating
bands, but the K251R mutant exhibited a significant downregulation in the shifted Miz1
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species. I examined two more possible non-consensus lysines for sumoylation which
however did not deliver further insight (data not shown).
The sumoylation site at lysine 251 is additionally surrounded by a stretch of acidic residues,
which enhances the efficiency of sumoylation by Ubc9. This kind of acidic cluster is also
used to correctly predict novel targets for Sumo modification [Yang et al., 2006]. Point
mutations of the valine or glutamic acid at the first and last position of the sumoyla-
tion consensus motif around lysine 251 recapitulated the phenotype of the K251R mutant
(Fig. 4.12 on page 73). The importance of not only the intact lysine but the motif as
a whole once more proves that the higher migrating bands represent sumoylated Miz1
species.
5.2.2. Arf promotes sumoylation of Miz1 by inhibiting Senp3
Several mechanisms were proposed to explain how Arf can induce sumoylation of proteins
to which it binds. Rizos et al. [2005] claimed that Arf interacts with the Sumo E2 enzyme
Ubc9 to allow direct discharge of Sumo to another Arf binding partner. In the case of
nucleophosmin however, another mode of action could be discovered. Arf does not directly
induce sumoylation but it inhibits desumoylation of NPM by the Sumo-specific protease
Senp3. Mechanistically, Arf promotes phosphorylation of Senp3 which is subsequently
ubiquitinated and degraded in the proteasome. The desumoylation of NPM is crucial for
its role in rRNA processing and depletion of Senp3 phenocopies the processing defect
observed upon depletion of NPM [Haindl et al., 2008; Kuo et al., 2008].
In vivo sumoylation assays revealed that overexpression of Senp3 represses sumoylation
of Miz1 while the dominant negative catalytically inactive Senp C352S mutant further
induced its sumoylation (Fig. 4.13 on page 74). This leads to the conclusion that Arf
induces Sumo modification of Miz1 by the same mechanism as it does for NPM. However,
enforced expression of Senp3 could lead to unspecific substrate recognition. RNAi-mediated
depletion of Senp3 would verify this proposed mode of action, but successful depletion of
Senp3 with shRNA also lead to rapid cell death which made further analysis impossible
(data not shown).
5.2.3. Endogenous sumoylation of Miz1 cannot be detected easily
To verify a biological relevance of the Sumo modification of Miz1, I tried to show
endogenous sumoylation. However, pulldown of endogenous Miz1 or low levels of infected
5.2. Miz1 can be sumoylated at a specific lysine which is induced by Arf 111
Miz1 upon overexpression of His-Sumo constructs did not show the characteristic size
shift as seen for the transfected Miz1 protein. Ubc9 or the catalytically inactive Senp3
mutant were expressed to enforce detection of visible sumoylation, this was also performed
in different cell lines, without success (data not shown).
The group of Frauke Melchior (ZMBH Heidelberg) performed endogenous large scale
IPs with Sumo1 and Sumo2 in HeLa cells followed by mass spectrometry analysis, in
unstressed as well as H2O2-treated cells. No peptides of Miz1 were found in this analysis
[Werner, 2011]. This might be due to a very transient Sumo modification of only a small
pool of endogenous Miz1, which is characteristic for the sumoylation of many proteins
[Johnson, 2004; Hay, 2005], or because a stimulus triggering in vivo sumoylation was
missing.
There are several reports about stress factors that increase the overall sumoylation
of cellular proteins, such as heat shock, osmotic stress, ethanol stress and high levels
of oxidative stress [Saitoh and Hinchey, 2000; Bossis and Melchior, 2006]. Successful
identification of a sumoylation inducing-agent for Miz1 could help to detect endogenous
sumoylation. Unfortunately, none of the treatments showed any effect on sumoylation of
exogenous protein (Fig. 4.14 on page 75).
All in all, an endogenous sumoylation could not be verified. It was thus focused on compar-
ing Miz1 wild type with the Miz1 K251R mutant to possibly expose phenotypic differences
between the two.
5.2.4. The non-sumoylatable Miz1 cannot be phenotypically distinguished from
Miz1 wild type in cell growth or DNA damage response
I used U2OS cells lentivirally infected with Miz1 and Arf constructs to assess cell growth
behavior. Colony assays and growth curve did not display any difference in growth
behavior upon expression of Miz1 wild type and the K251R mutant. Both slowed down
cell growth, which can be assigned to the expression of cell cycle inhibitors upon Miz1
infection [Staller et al., 2001]. Arf alone also lead to growth retardation with an additive
effect of Miz1+Arf expression. Cells did not go into anoikis at this point as seen before
upon retroviral infection and selection. The selection stress with two different antibiotics
might be needed for the cells to activate the anoikis program, probably because this leads
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to elevated Myc levels.
Miz1 plays an active role in DNA damage control by inducing transcription of p21 and thus
cell cycle arrest in response to UV stress. It also releases TopBP1 from the chromatin which
induces Atr to activate DNA damage response proteins such as Chk1 and p53. Enforced
expression of Miz1 by infection in LS174T cells has been shown to enhance and prolong
this response [Herold et al., 2008]. As this is one of the best characterized functions of
Miz1, it was assessed if Miz1 wild type and the K251R mutant behave differently in this
context. However, also in this assay these two proteins could not be distinguished. They
both induced an Atr-dependent response visualized as phosphorylation of Chk1 as well as
a G1 and S phase arrest in the FACS analysis following UV treatment. The increased
subG1 content at later time points for both expression of Miz1 wild type and the non-
sumoylatable mutant could be ascribed to additional stress by the very high Miz1 infection
levels which were achieved by lentiviral infection in comparison to the retroviral infection
in Herold et al. [2008].
5.2.5. Microarray analysis did not reveal different gene expression patterns
between Miz1 wild type and the non-sumoylatable mutant
I was unable to show that the known functions of Miz1 in growth arrest and UV response
are affected by sumoylation. For a more global approach, I assessed if expression of
Miz1 wild type and the K251R mutant induce differential gene expression patterns. The
analysis revealed that Arf broadens the spectrum of both Miz1 wild type and K251R to
modify genes (Fig. 4.17 on page 80) as has already been observed in [Herkert et al., 2010].
Direct comparison of genes that are either up- or downregulated at least twofold in the
Miz1 wild type or K251R conditions, with and without Arf, showed that there always is a
highly significant overlap between the two Miz1 conditions. This overlap is even increased
if the threshold for regulation is raised to a threefold or fourfold regulation (not shown).
This and visualization of the differential regulated genes in a dot plot (not shown) lead
to the conclusion, that almost none of the genes that seem to be regulated exclusively by
Miz1 wild type or the K251R mutant showed a pronouncedly different regulation. In fact,
virtually all these genes clustered around one or the other side of the the chosen cutoff value.
GO term analysis did not point to a particular group of genes which are differentially
regulated between the Miz1 wild type and the K251R mutant condition, with or without
Arf expression. I could reproduce that genes involved in cell adhesion are regulated by
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Miz1+Arf, but also by Miz1 alone and the K251R mutant and K251R+Arf. I however
could not find the exact same genes used for validation of the microarray in Herkert et al.
[2010] among the regulated targets in this array. Lentiviral infection used for the assays
in this work does not immediately induce anoikis, as retroviral infection with subsequent
selection did in the previous experiments. This difference could reflect the different
targets out of the group of cell adhesion genes that were regulated in this analysis and the
previous microarray.
To still be able to identify a difference between Miz1 wild type and the K251R mutant,
I picked out four groups of genes that displayed specific patterns of gene regulation.
Among these, the group which displayed a downregulation of gene expression only in the
Miz1+Arf condition comprised the most members. These genes could possibly experience
a downregulation upon overexpression of Arf because of subsequent sumoylation of Miz1,
probably via induction of heterochromatinisation as suggested in 5.1.2. To validate the
results of the microarray for these genes, I conducted qRT PCR experiments. Even though
the downregulation in the Miz1+Arf condition could be reproduced in all but one case,
the obtained values did not fit the overall pattern with Miz1+Arf being the exception of
downregulation among the other conditions. In contrast to that, randomly picked genes
with strong up- or downregulation in any condition could be validated effortlessly (not
shown).
It should be noted that for validation of the genes out of the only Miz1+Arf down group,
I picked out the genes with the most differential regulation for examination by qRT PCR.
A closer look on these genes revealed that all of their expression patterns were detected
with several probes, either for the exact same nucleic acid sequence or another sequence
in the same transcript. Interestingly, almost all of these probes showed an inconsistent
regulation for the same gene. Lukas Rycak evaluated this throughout the whole array:
about 14% of genes exhibited a different regulation among probes (threshold=1 for
the maximal difference of M-values among the same gene) [Rycak, 2012]. It is thus
possible that the microarray analysis fails to be reproducible via qRT PCR because a
group of genes that follows the `only Miz1+Arf down pattern does not really exist.
Picking out genes that follow this pattern may select for genes with dissimilar probe results.
In sum, no genes were found that are regulated in a profoundly different way comparing
Miz1 wild type and the non-sumoylatable mutant, either with or without Arf. This might
be due to the fact that Miz1 is simply not sumoylated upon mere overexpression of low
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levels of Miz1 and Arf, as sumoylation could also not be visualized under these conditions.
Probably an additional trigger for attachment of Sumo to Miz1 is needed, or sumoylation
occurs only in a certain phase of the cell cycle as has been observed for example for
BRCA1 [Vialter et al., 2011]. Expression of Miz1 K251R together with Arf did not
relieve repression of cell adhesion genes, which presumably means that sumoylation is
not necessary for heterochromatinisation upon formation of the Arf/Myc/Miz1 complex
after all. However, as a different set of cell adhesion genes was regulated comparing this
microarray and the one from Herkert et al. [2010], it might be that the gene expression
profiles differ for example in a temporal way and thus cannot really be compared.
Another explanation could involve varying levels of Myc. Activation of Arf reportedly only
occurs in response to an oncogenic trigger such as substantially elevated levels of Myc, and
high levels of Myc might be needed for the trimeric Arf/Myc/Miz1 complex to unfold its
full potential. Lentiviral infections in U2OS cells did not trigger anoikis compared to the
retroviral infection used for the microarray in Herkert et al. [2010], even though expression
of Miz1 and Arf was even higher with the lentiviral infection method. It is conceivable that
selection stress upon retroviral infection upregulates Myc in U2OS cells which is needed
for proper function of the Arf/Myc/Miz1 complex. Future experiments should verify this
by inducing oncogenic levels of both Arf and also Myc in an appropriate cell line relevant
for the anoikis phenotype such as primary epithelial cells.
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5.3. Myc gets sumoylated at many different sites
We discovered that Arf induces a Myc/Miz1 repressive complex and at the same time
promotes sumoylation of Miz1. In order to complete the picture, I also tested if Myc could
be sumoylated as well.
5.3.1. C-Myc and N-Myc get sumoylated by both Sumo isoforms
I performed in vivo sumoylation assays with exogenous protein followed by Western Blot
analysis. Both c-Myc as well as N-Myc displayed a whole array of higher migrating
bands, starting with a size shift of about 45 kDa and reaching up higher than 170 kDa
(Fig. 4.19 on page 86). This pattern phenotypically differed profoundly from the few
higher migrating bands observed upon Sumo attachment to Miz1. Arf did not induce
sumoylation of Myc, as it did for Miz1 (not shown). Direct Sumo1 and Sumo2 blots of
pulldown samples revealed that expression of N-Myc stabilized sumoylated proteins in
general. This probably results from the fact that non-attached Sumo protein is highly
unstable, and expression of a common sumoylation target may increase overall levels of
stable Sumo. The very high turnover of the Sumo modification may consequently allow
for other proteins to be increasedly sumoylated as well.
Depletion of Ubc9 as the only E2 enzyme in the sumoylation process severely diminished
higher migrating Myc bands in the His-Sumo pulldown (Fig. 4.20 on page 88). These must
thus either represent sumoylated species or sumoylation must be necessary for follow-up
posttranslational modifications. The ladder of shifted bands cannot be assigned to chain
formation, as it also occurs upon modification with Sumo1 as well as the Sumo2 K11R
mutant which cannot form chains anymore. Phenotypically, the modification pattern
strongly resembles ubiquitination. However, polyubiquitination of the Sumo protein
itself when attached to Myc did not occur. Sumoylation of N-Myc did not result in
increased ubiquitination and could also not be diminished by treatment with proteasome
inhibitors. The only possible interpretation of the particular sumoylation phenotype is
thus a multisumoylation at many different lysines in the Myc protein.
5.3.2. Myc is preferredly sumoylated at several C-terminal lysines
Sumoylation often occurs within the defined sumoylation consensus motif Ψ-K-X-E/D, for
example in Miz1 (see 5.2.1 on page 109). C-Myc does not contain such a site, and mutation
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of the two existing consensus motifs in N-Myc does not abrogate sumoylation. This was
already expected from the notion that Myc must get multisumoylated at several different
lysines. Mutants of Myc that contained lysines either only in the N-terminal or C-terminal
domain did not really help in narrowing down a preferred region for sumoylation (Fig. 4.22
on page 91). Thus, I assessed mutants of Myc containing only single intact lysines one
by one for their potential to be sumoylated (Fig. 4.23 on page 93). The analysis revealed
that there is a cluster of about seven preferred lysines for modification by Sumo which
however are not the only targets, as depletion of these lysines reduced sumoylation but
did not completely abolish it (Fig. 4.24 on page 94). Finding the specific sumoylated
lysines would have made it possible to compare Myc wild type to a non-sumoylatable
mutant. However, as virtually all lysines bear the potential to become sumoylated, one
would have to compare the K-less Myc with the wild type version. As lysines in Myc can
also be ubiquitinated and acetylated [Kim et al., 2011; Vervoorts et al., 2003], it would be
pointless to pursue such an analysis wanting to look for sumoylation-specific effects.
The sumoylation consensus motif recruits Ubc9 directly to the inherent lysine [Bernier-
Villamor et al., 2002]. The lack of a sumoylation consensus site in c-Myc already gave a
hint to the later observation that no particular lysines in Myc are the sole acceptors of this
modification, as had been shown before for other proteins without consensus sites [Yan
et al., 2007]. Ubc9 may still interact with a region distant to the sumoylation site, as seen
for AP2 or N-CoR [Eloranta and Hurst, 2002; Tiefenbach et al., 2006]. Another possible
explanation of how Myc attracts the sumoylation machinery could be that Myc recruits
Sumo-loaded Ubc9 via an internal SIM (Sumo interacting motif), which had been shown
for USP25 [Mohideen and Lima, 2008] and will be discussed in 5.3.4.
5.3.3. Endogenous sumoylation of Myc could not be detected
I was not able to visualize endogenous sumoylation of Myc in pulldown experiments per-
formed according to previously conducted experiments with Miz1 (see 5.2.3). No peptides
of c-Myc or N-Myc were found in the endogenous large scale IPs with Sumo1 and Sumo2
performed in the group of Frauke Melchior from the ZMBH Heidelberg [Werner, 2011].
None of the stress factors known to induce overall sumoylation levels in cells were able to
induce sumoylation of exogenous Myc and could thus not be exploited to trigger endoge-
nous sumoylation of the protein (Fig. 4.25 on page 95). It can be concluded that either
the steady state sumoylation of Myc is extremely low or modification by Sumo needs an
unidentified trigger.
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5.3.4. A conserved motif in Myc could not be validated as a Sumo interacting
motif
The previously described PEST sequence in c-Myc is one of the most conserved areas
among different Myc homologues and paralogues (Fig. 4.26 on page 96). This sequence
fulfills all criteria for a reverse Sumo interacting motif (SIMr). While hydrophobic and
aromatic amino acids in Sumo are arranged to form a groove, the SIM peptide has an
extended shape that can be embedded in this groove to form an intermolecular β-grasp
fold [Kerscher, 2007]. SIMs play an important role in the effector proteins that mediate
the physiological consequences of sumoylation, but they can also mediate sumoylation of
the protein containing the SIM [Rytinki et al., 2009; Mohideen and Lima, 2008]. Both
functions could be interesting for the Myc protein: On the one hand several known
coactivators of Myc have been shown to be sumoylated upon heat shock and a SIM could
thus provide an additional interaction surface for Myc [Golebiowski et al., 2009]. On the
other hand sumoylation of Myc itself could be mediated via a SIM motif as c-Myc lacks
an internal sumoylation consensus site that recruits Ubc9 to the protein.
To test if the conserved sequence in Myc is a valid Sumo interacting motif, I generated
mutants that either lacked the whole conserved SIM area or just the core amino acids.
His-Sumo pulldowns revealed that the possible SIM is not needed to induce sumoylation of
Myc (Fig. 4.26 on page 96). In vitro binding assays showed a weak but consistent binding
of c-Myc and N-Myc to Sumo1, which could however also be detected with a mutant
lacking the core amino acids of the conserved motif (Fig. 4.27 on page 98). It must thus
be concluded that the possible SIM motif in Myc is not necessary for sumoylation of Myc
itself and could also not be verified to be an actual Sumo interacting motif in the in vitro
binding assay.
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Appendix A.
List of abbreviations
A selection of abbreviations that can be found in this thesis are explained below. Further-
more the abbreviations of the IUPAC (International union of pure und applied Chemistry)
and of the SI-System (Système international d'unités) were used.
A.1. Prefixes
abbreviation prefix factor
p Pico- 10-12
n Nano- 10-9
μ Mikro- 10-6
m Milli- 10-3
c Centi- 10-2
k Kilo- 103
Table A.1.: abbreviations for prefixes and multiplication factors
A.2. Units
A ampere
Da dalton
g gram
h hour
J joule
l liter
XXIV Appendix A: List of abbreviations
m meter
min minute
M mol/l
mol mol
OD optical density
s second
U unit
vol. volume
v/v volume per volume
w/v weight per volume
°C degree celsius
A.3. Proteins, protein domains and other biomolecules
A adenine
ATP adenosine-5-triphosphate
A alanine
aa amino acid
R arginine
bp basepair(s)
BTB broad-complex, tramtrack and bric à brac
C cytosine
cDNA complementary DNA
DNA deoxyribonucleic acid
dNTPs deoxyribonucleoside-5'-triphosphate (dATP, dCTG, dGTP, dTTP)
A.4. Chemicals and solutions XXV
G guanine
GFP green fluorescent protein
GST glutathione-S -transferase
GTP guanosine-5'-triphosphate
HRP horseradish peroxidase
K lysine
nt nucleotide(s)
POZ pox virus and zinc finger
RNA ribonucleic acid
T thymine
TopBP topoisomerase-binding protein
ZBTB4 zinc finger and broad-complex, tramtrack and bric-a-brac (BTB)-domain-
containing protein 4
ZF zinc finger
A.4. Chemicals and solutions
APS ammoniumpersulfate
ddH2O bidestilled water
DMEM Dulbeccos Modified Eagle-Medium
DMSO dimethylsulfoxide
DTT dithiothreitol
EDTA ethylendiamintetraacetate
FCS fetal calf serum
FBS fetal bovine serum
XXVI Appendix A: List of abbreviations
NEM N -ethylmaleimide
PBS phosphate-buffered saline
PVDF polyvinylidenfluoride
SDS sodium dodecyl sulfate
TBE Tris-borate-EDTA-buffer
TBS Tris-buffered saline
TBS-T Tris-buffered saline with tween-20
TE Tris-EDTA-buffer
TEMED N,N,N',N'-tetramethylethylendiamine
Tris Tris-(hydroxymethyl)-aminomethan
A.5. Other abbreviations
abs. absolute
approx. approximately
ATCC American Type Culture Collection
ECL enhanced chemoluminescence
E. coli Escherichia coli
FPLC fast protein liquid chromatography
Fig. Figure
Inc. Incorporated
IP immunoprecipitation
PAGE polyacrylamide-gelelectrophoresis
PCR polymerase chain reaction
qPCR quantitative PCR
A.5. Other abbreviations XXVII
rpm rotations per minute
RT room temperature
o./n. over night; 16-20 h
S1 security level 1
S2 security level 1
wt wild type
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